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Two important facets that are found in many biologically active 
compounds and complex natural products are chirality and heterocyclic motifs, in 
particular lactones and lactams.  Biologically active compounds found in nature 
often need to be synthesized due to the fact that only a minute amount of the 
active molecule is produced. 
In the research described herein, an asymmetric methodology known as 
desymmetrization is utilized to produce enantioenriched compounds that can be 
used as building blocks in the synthesis of biologically active natural products.  
We have developed an efficient synthesis of enantioenriched γ-and δ-lactones 
via an enantioselective desymmetrization.  In this process, racemic diesters in 
the presence of a chiral Brønsted acid selectively undergo cyclization to yield 
enantioenriched γ- and δ-lactones.  The methodology is also expanded to include 
the synthesis of spirocyclic molecules.  The desymmetrization is highly selective 
and the products formed contain an all-carbon quaternary stereocenter that 
would be difficult to install using other methodologies.
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CHAPTER I 
 
INTRODUCTION 
 
1.1  Chirality and Heterocyclic Compounds 
Two important components that are commonly found in various 
biologically active compounds are chirality and heterocyclic structures.  Many 
biologically important compounds contain a chiral center whose absolute 
configuration is vital to its physiological activity.  The specific geometry of a 
bioactive molecule can dictate its interaction with a chiral protein or enzyme.  
Thus, chirality plays a critical role in the activity of biologically important 
compounds such as drug candidates and complex natural products.  A classic 
example of the importance of chirality is the infamous drug, thalidomide (Figure 
1). 
 
 
 
Figure 1. (R)- and (S)-Thalidomide 
 
 
Racemic thalidomide was first introduced to the market in the early 1950s and  
 
was prescribed to treat nausea in pregnant women.2  It was withdrawn from the 
2 
 
market in 1961 due to the fact that it caused birth malfunctions such as  
 
as phocomelia.3  It is proposed that the R enantiomer (1) is the effective anti- 
 
nausea agent whereas the S enantiomer (2) is the cause of the negative side  
 
effects.  Thalidomide is currently banned in many countries because of its ability  
 
to racemize in vivo thus the enantiomers can interconvert in the body.4 The  
 
thalidomide crisis brought to light that the absolute configuration of drug  
 
compounds is important and the different stereoisomers of the molecules  
 
may have different biological activities.  This has caused the FDA and the  
 
pharmaceutical industry to focus on the production of single enantiomer drugs  
 
rather than racemic mixtures. 
 
Compounds found in nature that are identified as medicinally beneficial to 
human health frequently exist as a complex mixture and are sometimes 
produced in such small quantities that they cannot be fully evaluated for their 
potential health advantages. A well-known example is the anticancer drug Taxol 
(3), a natural product isolated from the extracts of the bark of the Pacific Yew, 
Taxus brevifolia (Figure 2).5 Taxol was first discovered in the early 1960s and 
exhibited significant cytotoxic and antileukemic activity for several cancers 
however its production in nature was limited.  The availability of the bark is 
sparse with a reported isolation yield of 0.014% and isolating a sufficient amount 
of taxol would lead to the depletion in the yew tree population.  Hence, the total 
synthesis of taxol became a prime synthetic target for organic chemists and has 
been of interest since the 1980s with several advancements being made.
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Figure 2.  The Anti-Cancer Drug, Taxol 
 
 
The exploration and future use of these significant materials often is 
parallel to the ability of a synthetic chemist to prepare them in an efficient and 
selective manner.  Thus, it is essential for synthetic chemists to develop facile 
high yielding syntheses for enantioenriched molecules such as drug candidates 
and biologically active natural products.  In particular, syntheses need to focus on 
chiral highly functionalized small molecules that can be building blocks for the 
synthesis of complex molecules.   
1.2  Asymmetric Methodologies 
The field of asymmetric methodology development has been of much 
interest due to the need for the synthesis of non-symmetric molecules. Types of 
methodologies that have been developed include kinetic resolutions and 
desymmetrizations.
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      1.2.1 Kinetic Resolution 
 Kinetic resolution is a synthetic technique which allows chemists to 
achieve separation of enantiomers in a racemic mixture by utilizing a chiral 
catalyst or reagent (Figure 3).6  In kinetic resolution, both enantiomers of a 
racemic starting material (SM) react with the chiral catalyst at different rates (kS 
and kR) to form an enantioenriched product (P).  The relative rate of the reaction 
is determined by the difference in the activation energies of each enantiomer in 
the rate limiting step (ΔΔG‡).  The difference of rates will result in the 
enantioenriched product (PS) as well as enantioenriched recovered starting 
material (SMR). The faster rate has the lower activation energy which leads to the 
enantiomeric product being formed selectively. Both PS and SMR have the 
potential of achieving up to 50% yield and 100% enantiomeric excess (ee).  The 
maximum possible yield of a single enantiomer compound is 50% due to the fact 
that you begin with a racemate.  However the theoretical total mass recovery of 
enantioenriched material is 100%.   
5 
 
 
Figure 3. General Schematic of Kinetic Resolution 
 
 
An example of a kinetic resolution can be seen in a recent publication from 
the Petersen lab which reported an efficient synthesis of α-substituted hydroxy 
esters via a kinetic resolution.7  Bulky racemic esters (4) in the presence of a 
chiral Brønsted acid selectively lactonize to yield a recoverable enantioenriched 
hydroxy esters (3) and produced enantioenriched lactones (5) (Figure 4).   
 
 
 
Figure 4. Synthesis of α-substituted Hydroxy Esters via Kinetic Resolution   
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    1.2.2. Desymmetrization 
 
Desymmetrization of prochiral molecules to yield enantioenriched products 
is a powerful synthetic technique and is a variant of kinetic resolution.8 
Desymmetrization begins with a symmetrical prochiral molecule that possesses a 
plane of symmetry and two enantiotopic groups (Figure 5).  A chiral reagent is 
introduced which allows for the differentiation of the two enantiotopic groups to 
yield an enantioenriched product.   In contrast to the kinetic resolution of a 
racemic mixture, in a desymmetrization the product has the potential result of 
100% yield and 100% ee.    
 
 
 
Figure 5. General Schematic of Desymmetrization 
 
 
An example of a desymmetrization can be seen in a recent publication 
which involves asymmetric bromolactonization of alkynes.9  The stereoselective 
synthesis of bromoenol lactones (7) via enantioselective halolactonizaton of 
nonconjugated alkynoic acids (6) was reported (Figure 6).  The produced 
bromoenol lactones contained a tetrasubstituted alkene and a quaternary 
stereocenter and were formed with high yield and excellent selectivity.
7 
 
 
 
Figure 6.  Asymmetric Bromolactonization 
 
 
1.3  Chiral Brønsted Acid Catalysts  
The desymmetrization of prochiral molecules to obtain chiral 
enantioenriched products with an enzyme or organocatalyst is a powerful 
synthetic technique.  In particular, the desymmetrization of prochiral diester 
malonates via enzyme-mediated partial hydrolysis has generated much synthetic 
interest.10 However, this technique is limited by enzyme instability and the 
difficulty in catalyst recovery and reuse. 
The use of chiral Brønsted acid catalysts is a rapid growing area in 
organocatalysis.11 Typical catalysts are based on TADDOL (8), thiourea (9), 
camphoric sulfonic acid (10), or BINOL phosphoric acids (11-14) (Figure 7).12  
The benefits of these catalysts are the low catalyst loadings, mild reaction 
conditions, and the application to a wide range of substrates
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Figure 7.  Examples of Chiral Brønsted Phosphoric Acid Catalysts 
 
 
The BINOL-based phosphoric acid catalyst 14 contains a triisopropyl 
phenyl group at the 3 and 3’ position and will be the catalyst of choice for the 
enantioselective cyclization processes discussed in later chapters.  The chiral 
acid serves to activate carbonyl compounds through either a hydrogen bonding 
event or full Brønsted acid catalysis (Figure 8).13  The catalyst selectively 
promotes cyclization of one enantiomer of a prochiral diester by initializing a 
nucleophilic attack of the carbonyl which is then followed by the release of the 
product and turnover of the catalyst.   
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Figure 8.  BINOL Phosphoric Acid Catalyst 14 and Carbonyl Activation 
 
 
It is proposed that because of steric clashing, one enantiotopic group of the 
diester substrate will bind preferentially to the chiral catalyst (complex 15 favored 
and complex 16 disfavored) (Figure 9).  The enantiotopic group that binds more 
favorably will then progress to the enantioenriched product. 
 
Figure 9.  Proposed Binding of Chiral Catalyst 14
10 
 
1.4  Conclusion 
In the research presented in this dissertation, the asymmetric 
methodology known as desymmetrization will be utilized to produce 
enantioenriched compounds that have the potential to be used as building blocks 
in the synthesis of biologically active natural products.  We describe an efficient 
synthesis of enantioenriched γ- and δ-lactones that contain an all-carbon 
quaternary stereocenter via an enantioselective desymmetrization.  Racemic 
diesters in the presence of a chiral Brønsted acid selectively undergo cyclization 
to yield enantioenriched γ- and δ-lactones.  The methodology is also expanded to 
include the synthesis of spirocyclic molecules.       
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CHAPTER II 
 
ASYMMETRIC SYNTHESES OF ENANTIOENRICHED LACTONES 
 
 
2.1  Introduction 
The stereoselective formation of all-carbon quaternary centers is typically 
achieved by the asymmetric construction of a new carbon-carbon bond.8  The 
challenge encountered with this approach is the steric repulsion between the 
carbon substituents.   A different method involves the desymmetrization of 
prochiral molecules which entails the formation of a quaternary center as 
separate from the enantiodetermining step (Figure 10).  The prochiral molecule 
17 contains a pre-existing all-carbon quaternary center and upon the introduction 
of a chiral catalyst, a new compound 18 is produced with an all-carbon 
quaternary stereocenter. 
 
 
Figure 10.  Desymmetrization of a Prochiral Molecule 
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The lactone motif is seen in many biologically active molecules, and in 
particular enantiopure lactones with a fully substituted carbon α to the carbonyl 
are common.  (+)-Hopeahainol A (19)14 which has proven to be an 
acetylcholinesterase inhibitor that is associated with Alzheimer’s disease and (S)-
camptothecin (20)15 which exhibits anti-cancer activity through topoisomerase I 
inhibition are two examples (Figure 11). 
 
Figure 11. Lactone Natural Products with an α-Chiral Center 
 
 
As recently published by the Petersen lab, the desymetrization of hydroxy 
diester 21a in the presence of chiral Brønsted acid 14 produced lactone 22a in 
high yield and excellent enantioselectivity (Figure 12).16 It is hypothesized that 
the reaction proceeds through selective activation of one of the esters with the 
chiral phosphoric acid followed by an intramolecular lactonization. Based on this 
13 
 
encouraging initial result, we also explored the full scope of the desymmetrization  
process and the utilization of the lactone product.  
 
 
Figure 12.  Initial Desymmetrization of Hydroxy Diester 
 
 
Construction of enantioenriched α-carboxy-γ-lactones such as 22a 
containing a quaternary center has been previously explored due to the high 
utility of such compounds.  Acylation of silyl ketene acetals has been 
accomplished with chiral DMAP derivatives,17 isothiourea,18 or thiourea 
catalysts,19 however results are limited to aryl R groups and/or a need for 
disubstitution of the γ-carbon.  Diastereoselective conjugate addition of an 
enolate equivalent is another strategy that has yielded some promising results, 
yet the scope of acceptable Michael acceptors is limited.20  Most recently, a 
method for the enantioselective -alkylation of -tert-butoxycarbonyllactones 
through phase-transfer catalysis was revealed, however substitution was limited 
to benzylic or allylic groups.21  The methodology described here, whereby a chiral 
Brønsted acid 14 catalyzes the 
14 
 
cyclization of a symmetric substrate to deliver an enantioenriched lactone, takes 
advantage of the differentiation of the two enantiotopic ester groups.  The lactone 
products obtained through variation of the methyl group to other substitution 
patterns are valuable compounds carrying a challenging all-carbon quaternary 
center (when R  H).  
2.2  Results and Discussion 
The synthesis of diester substrates such as 21a begins with the mono 
alkylation of di-tert-butyl malonate (23) with sodium hydride and methyl iodide.  A 
second alkylation with 2-bromoethyl acetate and subsequent hydrolysis yields 
hydroxy diester 21a in 3 short steps and 52% overall yield (Figure 13).  
 
 
Figure 13. Preparation of Prochiral Substrates 
 
 
Various substrates (Table 1, 21b–g) were studied, ranging in length and 
branching.  Each substrate was prepared as substrate 21a, but using the 
appropriate alkyl halide in the first alkylation step.   Gratifyingly, modification of 
the original methyl group in 21a with larger groups such as ethyl 21c, isopropyl 
15 
 
21d, allyl 21e  and benzyl 21f all yielded enantioenriched lactones containing an 
all-carbon quaternary stereocenter that would be difficult to install using other 
methodologies in good to excellent yields (67–97%) and enantiopurity greater 
than 90%.  Replacement of the methyl group with a proton 21b, generated 
lactone 22b in excellent yield and good enantiopurity (93% yield and ee = 91%).                
Based on the successful generation of enantioenriched γ-lactones, the 
desymmetrization was expanded to include preparation of a δ-lactone.  
Lactonization of the one carbon homologated hydroxyl diester 21g, which was 
prepared through hydroboration and oxidation of methyl, allyl di-tert-butyl 
malonate, occurred with the Brønsted acid chiral catalyst 14 in dichloromethane 
at room temperature to yield lactone 22g in good yield (84%) and selectivity 
(86%). 
Table 1. Lactone Substrate Scope. 
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In order to fully exploit the desymmetrization process, lactone 22a was 
prepared on a 1.3 gram scale from 1.9 grams 21a and 20 milligrams catalyst 14, 
yielding lactone 22a in 95% yield and 98% ee.  To further explore the scalability 
and flexibility of the desymmetrization process, lactone 22a was prepared on a 
5.9 gram scale from 8.9 grams of 21a and 0.23 grams catalyst 14, yielding 
lactone 22a in 96% yield and 98% ee (submitted for publication in Organic 
Syntheses).   The reaction conditions such as solvent, temperature and catalyst 
load were varied and pleasingly no selectivity loss was observed as seen in 
Figure 14.  One of the conditions for the submission to Organic Syntheses was 
that the cost of reagents and starting materials could not exceed $500.  To 
achieve this, the catalyst load was lowered from 5 mol% to 1 mol%.  We also 
were able to decrease the reaction time from 4 days to 2 days by using toluene 
at 80 °C.    
 
Figure 14.  Scale-Up Reaction of Lactone 22a 
 
 
Lactones with enantioenriched all-carbon containing stereocenters such 
as 22a prepared from prochiral diesters in good yield and enantioselectivity are 
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prime candidates for incorporation into more complex molecules. The utility of 
these highly enantioenriched lactone substrates was shown through the 
transformation of lactone (–)-22a into a variety of highly functionalized building 
blocks (Figure 15).  Successful reduction of lactone 22a with lithium tri-tert-
butoxyaluminum hydride yielded diol (–)-24 in 92% yield and without loss of 
enantiopurity (ee = 98%).22  Amide ester (–)-25 was formed upon treatment of 
lactone 22a  with the benzyl amine in 76% yield and retention of 98% ee.23  
Cleavage of the tert-butyl ester of lactone 22a  with TFA followed by conversion 
of the resulting carboxylic acid to the acyl azide and subsequent Curtius 
rearrangement yielded amido lactone (+)-26 in 56% overall yield and 98% ee.24  
Treatment of lactone 22a with aqueous ammonium hydroxide followed by 
acetylation of the resulting alcohol yielded an amide ester that then underwent a 
Hofmann rearrangement with lead (IV) acetate and hydrolysis with potassium 
carbonate to give α-amino ester (+)-27 in 65% overall yield and 96% ee.25  
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Figure 15. Transformations 
 
 
The absolute configuration of lactone products 22a–22g was assigned as 
R through comparison of a known optical rotation value.  Diol (+)-28 is readily 
prepared from lactone (+)-22f and the sign of rotation matches literature values 
for R-28 (Figure 16).26 
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Figure 16. Determination of Absolute Configuration 
 
 
2.3  Conclusion 
 In summary, we have developed a highly generalized and scalable 
desymmetrization of hydroxy di-tert-butyl esters to produce enantioenriched 
lactones in high yields and selectivities, many of which contain a challenging all-
carbon quaternary center that are difficult to prepare using other methods.  The 
lactone products readily undergo transformations to generate highly 
functionalized small molecules that are potentially valuable intermediates in the 
synthesis of bioactive molecule.
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CHAPTER III 
 
ASYMMETRIC SYNTHESES OF ENANTIOENRICHED SPIROCYCLIC 
COMPOUNDS 
 
 
3.1  Introduction 
Construction of enantioenriched spirocyclic molecules containing a 
quaternary center has become of substantial synthetic interest due to the high 
utility of such compounds and the commonality of the motif in complex natural 
products.  Azaspirene (29)27 which is an angiogenesis inhibitor associated with 
cancer therapy and horsfiline (30)28 which exhibits analgesic effects are two 
examples (Figure 17). 
 
 
Figure 17. Natural Products Containing a Spirocyclic Motif 
 
 
The construction of spirocyclic compounds is a synthetic challenge due to 
their conformational rigidity. One approach for the formation of a spirocenter is a 
catalytic asymmetric process.29 A recent publication describes a catalytic 
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asymmetric three component 1,3-dipolar cycloaddition synthetic method for the 
construction of the center.30  The enantioselective catalytic method involves 
reacting methyleneindolinones 31 with amino esters 32 and aldehydes 33 by 
using phosphoric acid catalyst 35 to yield enantioenriched spirocyclic compounds 
34 in excellent yields and selectivities (Figure 18).                                
 
Figure 18. Three Component 1,3-Dipolar Cycloaddition 
 
 
Thus, our aim was to expand the desymmetrization of diesters to 
incorporate spirocyclic bislactone and lactone-lactam targets.  The approach will 
include a double cyclization process which will begin with a selective 
lactonization via chiral catalyst 14 to set the absolute configuration of the 
quaternary carbon center followed by spirocyclization via an achiral acid catalyst 
(Figure 19). 
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Figure 19.  Synthetic Approach for Spirocycles 
 
 
Therefore, the methodology described here, whereby chiral Brønsted acid 
14 catalyzes the cyclization of a symmetric substrate to deliver an 
enantioenriched lactone, takes advantage of our previously established ester 
activation by a chiral acid. 
3.2  Results and Discussion 
     3.2.1 Preparation of Spirocyclic Bislactones 
The synthesis of bislactones diester substrates begins with the mono 
alkylation of di-tert-butyl malonate (23) utilizing sodium hydride and 2-
bromoethylacetate.  This is followed by a second alkylation with the appropriate 
benzyl ether and sodium hydride yielding masked diol substrates 36a-b in up to 
60% yield (Figure 20). 
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Figure 20. Preparation of Prochiral Substrates 
 
 
Next, deprotection of one of the alcohols is accomplished via potassium 
carbonate and is followed by asymmetric lactonization with chiral catalyst 14 to 
yield enantioenriched γ-lactone 37a-b with yields up to 96% (Figure 21).  
Removal of the benzyl group is carried out by hydrogenolysis followed by achiral 
lactonization with p-toluenesulfonic acid (p-TSA) to yield enantioenriched 
spirocyclic bislactones 38a-b (see Table 2).         
 
Figure 21. Lactonizations of Spirocyclic Bislactones  
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     3.2.2. Preparation of Spirocyclic Lactone-Lactam   
Preparation of the spirocyclic lactone-lactam was carried out in a similar 
fashion to our previous substrates. The synthesis begins with the mono alkylation 
of di-tert-butyl malonate (23) utilizing sodium hydride and the appropriate benzyl 
ether.  Next, second alkylation is performed using N-tosylaziridine with sodium 
hydride to yield compounds 39 (65% yield) (Figure 22).   
 
 
 
Figure 22. Preparation of Prochiral Substrates 
 
 
The removal of the benzyl group is carried out by hydrogenolysis followed by 
asymmetric lactonization with chiral catalyst 14 to yield enantioenriched γ-lactone 
40 in quantitative yields (Figure 23).  Next, an achiral lactamization is carried out 
with trifluoroacetic acid (TFA) to yield enantioenriched spirocyclic lactone-lactam 
41 (see Table 2).         
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Figure 23. Cyclizations of Spirocyclic Lactone-Lactam 
 
  
     3.2.3. Results of Spirocyclizations 
As hypothesized, the proposed desymmetrization syntheses yielded 
enantioenriched spirocyclic compounds containing an all-carbon quaternary 
stereocenter that would be difficult to install using other methodologies.   Each 
spirocyclic compound 43b-c exhibited good to excellent yields and enantiopurity 
greater than 80% ee (Table 2).  
 
Table 2. Spirocyclic Compounds  
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3.3 Future Work 
Future work for the enantioenriched spirocycle 43c will include x-ray 
crystallography analysis for absolute configuration assignment.  In addition, the 
preparation of spiro-pyrrollidine/tetrahydrofuran 45 will be performed utilizing 
compound 43c.  The spirocyclic lactone-lactam 43c will be treated with 
Lawesson’s reagent followed by reduction through hydrogenation over Raney 
nickel to give spirocyclic pyrrollidine-lactone 44.31  Next, reduction of the lactone  
will give the diol followed by cyclization under Mitsunobu conditions to yield spiro- 
pyrrollidine/tetrahydrofuran 45 (Figure 24).32 
 
 
Figure 24.  Reduction of Spirocycle 43c 
 
 
Future work will also include expanding the synthesis to include spirocyclic 
bislactams.  Preparation of bislactams will be carried in a similar fashion as 
described for the spirocyclic bislactones and lactone-lactams.  The synthesis will 
began with the mono alkylation of di-tert-butyl malonate (23) with sodium hydride 
and N-tosylaziridine then the second alkylation is performed using an aziridine 
with a different protecting group (PG) such as nosyl or benzyl with sodium 
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hydride to yield compound 46 (Figure 25). Selective cyclization will be carried out 
using catalyst 14 followed by achiral cyclization with p-TSA to yield 
enantioenriched bislactam 47.  
 
 
Figure 25.  Proposed Synthesis for Enantioenriched Spirocyclic Bislactams 
 
 
3.4  Conclusion 
 
In summary, we have developed a desymmetrization of hydroxy and 
amino diesters to produce enantioenriched spirocyclic bislactones and lactone-
lactams in high yields and selectivities all of which contain a challenging all-
carbon quaternary center that are difficult to prepare using other methods.    
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CHAPTER IV 
 
ASYMMETRIC SYNTHESES OF ENANTIOENRICHED LACTAMS 
 
 
4.1  Introduction 
The development of an asymmetric Brønsted acid catalyzed cyclization 
was expanded to include enantioenriched lactams containing a quaternary center 
at the alpha position.  Nitrogen containing molecules are commonly seen in 
biologically important compounds and new methods to generate carbon-nitrogen 
bonds selectively are continuously needed.  In particular, functionalized γ-
lactams are prevalent among the structures of a large number of biologically 
active natural products and pharmaceutical targets.33  Salinosporamide A (48)34 
which is a bioactive metabolite that exhibits anticancer activity and (–)-
pramanicin (49)35 which exhibits antifungal activity are two examples (Figure 26).
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Figure 26. Lactam Natural Products 
 
 
Asymmetric methodologies have been previously explored for the 
construction of enantioenriched lactams containing a quaternary chiral center 
because of their usefulness.  A recent publication reports the application of the 
desymmetrization of prochiral diesters in the total synthesis of (–)-leuconoxine 
(51) (Figure 27).36 The selective formation of δ-lactam 50 was a key step in the 
overall synthesis of compound 51 and set the absolute configuration of the 
quaternary center in the molecule.    
 
Figure 27. Desymmetrization Step in the Total Synthesis of (–)-Leuconoxine. 
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Our objective is to expand the desymmetrization of diesters to include the 
synthesis of enantioenriched γ-lactams containing an all-carbon quaternary 
center.  The approach will involve prochiral amino diester 52 undergoing a 
selective lactamization via chiral catalyst 14 to obtain enantiopure lactam 53 
(Figure 28).  Because amines are more nucleophilic and basic than alcohols, 
modification of the amino group to make it less reactive will be taken into 
consideration. 
    
Figure 28. Synthetic Approach for Lactams 
 
 
4.2 Results and Discussion 
The initial synthesis of diester substrates such as 54 begins with the mono 
alkylation of di-tert-butyl malonate (23) with sodium hydride and methyl iodide 
(Figure 26).  A second alkylation with N-tosylaziridine yields compound 54 in 2 
short steps with an overall yield of 78%.  Enantioselective cyclization of 
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compound 54 in the presence of chiral Brønsted acid 14 resulted in lactam 55 in 
high yield and excellent enantioselectivity. 
 
Figure 29. Initial Desymmetrization of Amino Diester 54a 
 
 
With the initial result using sulfonamide 54a, a protecting group screen 
was performed to ensure the tosyl protecting group was the best option for the 
selective lactamization (Table 3).  Various nitrogen protecting groups were 
screened such as benzoyl37 and nosyl38 and the asymmetric cyclization of each 
resulting amino diester 56b-d was performed.  Even though N-nosylaziridine 
produced promising results, it was decided that N-tosylaziridine was the 
protecting group of choice.
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Table 3.  Protecting Group Screen 
 
 
In order to explore the scope of the reaction, various substrates (Table 4, 
54a–e) were synthesized, ranging in chain length, branching, and size.  Each 
substrate was prepared as substrate 54a, but using the appropriate alkyl halide 
in the first alkylation step.   Modification of the original methyl group in 54a with 
larger groups such as allyl 54c and alkynyl 54e all yielded enantioenriched 
lactams containing an all-carbon quaternary stereocenter in good yields and 
enantiopurity. 
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Table 4. Lactam Substrate Scope 
 
 
 
Replacement of the methyl group with a proton generated lactam 59 and 
its activity was evaluated against Staphylococcus aureus (Figure 30).  The 
preliminary assay can be seen in Figure 30 and was conducted by the Cech 
laboratory of UNC-Greensboro Department of Chemistry and Biochemistry.  The 
test compound demonstrates dose-dependent inhibition of the growth of 
Staphylcoccus aureus (strain NCTC-8325-4) and exhibited moderate potency 
with an IC50 of 55 μM. 
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Figure 30.  Antimicrobial Activity of Lactam 59 Against Staphylococcus aureus. 
 
 
4.3 Current Status 
Compared to the desymmetrization of hydroxy diesters, the preparation of 
γ-lactams has been much more challenging.  As seen in Table 4, a consistent set 
of optimized reaction conditions was not established and variation of solvent and 
temperature was often required to obtain the needed reactivity.  Unfortunately, 
after generating the above table, a reproducibility issue was encountered.  It was 
first brought to attention in the scale up reaction of the enantioselective 
cyclization of compound 54a in the presence of chiral Brønsted acid 14 to yield 
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lactam 55a.  The primary result of the stated reaction was the isolation of 
recovered starting material 54a.  At the same time, reproduction of other entries 
in Table 4 was attempted with similar unsuccessful outcomes. Several reaction 
conditions were analyzed in hopes of resolving the issue.  Catalyst load, solvent, 
concentration and temperature screenings were performed (Table 5 and 6).  
However, the issue has not been corrected and still remains a goal.  
Table 5.  Reaction Conditions for Achiral Lactamization  
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Table 6.  Reaction Conditions for Chiral Lactamization  
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Table 6 cont. 
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4.4 Conclusion 
The initial results seen in Table 4 are promising and it is an ongoing 
process to overcome the reproducibility issue.  New avenues are currently being 
explored such as catalyst type for both achiral and chiral lactamization.  For 
example, consistent results have been obtained in the achiral lactamization of  
amino diester 54 with trifluoroacetic acid (TFA) which resulted in lactam 60 in 
good yield (90%) (Figure 31).      
 
 
Figure 31.  Achiral Lactamization using TFA 
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CHAPTER V 
 
EXPERIMENTAL 
 
 
5.1  General Information 
 
Unless noted, all solvents and reagents were obtained from commercial 
sources and used without further purification; anhydrous solvents were dried 
following standard procedures.  The 1H and 13C nuclear magnetic resonance 
(NMR) spectra were plotted on 400 and 500 MHz spectrometer using CDCl3 as a 
solvent at rt. The NMR chemical shifts (δ) are reported in ppm. Abbreviations for 
1H NMR: s = singlet, d = doublet, m = multiplet, b = broad, t = triplet, q = quartet, 
p = pentet. The reactions were monitored by TLC using silica G F254 precoated 
plates. Flash chromatography was performed using flash grade silica gel (particle 
size: 40-63 µm, 230 × 400 mesh). Enantiomeric excess was determined by GC 
analysis and HPLC analysis.  IR data was obtained with a FTIR spectrometer 
one with frequencies reported in cm-1. High Resolution Mass Spectra were 
acquired on an Orbitrap XL MS system.  The specific rotations were acquired on 
an analytical polarimeter.
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5.2  Synthesis of Compound 22a 
     5.2.1 Di-t-butyl 2-methylmalonate intermediate 
 
 
 
Figure 32. Di-t-butyl 2-methylmalonate Intermediate 
 
 
To a solution of sodium hydride (60% in mineral oil, 0.89 g, 22.3 mmol) in 
THF (15 mL) was added di-t-butyl malonate dropwise (4.83 g, 22.3 mmol) and 
the solution was stirred for 10 minutes at rt.  To the reaction mixture, 
iodomethane (1.39 mL, 22.3 mmol) was added dropwise and the solution was 
stirred for 24 h at rt.  The reaction was quenched with saturated NH4Cl (6 mL) at 
0 °C, phases were separated, and aqueous phase was extracted EtOAc (2 x 15 
mL).  The combined organic phases were dried over MgSO4 and concentrated.  
The residue was purified by flash chromatography on silica gel (5→15% EtOAc 
in hexanes) to afford the di-t-butyl 2-methylmalonate intermediate as a colorless 
oil (3.61 g, 70% yield). 1H NMR (500 MHz, CDCl3) δ 3.24 (q, J = 7.2 Hz, 1H), 
1.41 (s, 18H), 1.33 (d, J = 7.2 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 169.7, 81.3, 
48.2, 28.0, 13.5; IR (neat) cm-1 2979, 1725, 1456, 1367, 1136, 848; HRMS 
(C12H22O4, ESI): calculated 253.1415 [M+Na]
+1, found 253.1403.
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     5.2.2 Acetyl methylmalonate intermediate 
 
 
 
 
Figure 33. Acetyl methylmalonate Intermediate 
 
 
To a solution of sodium hydride (60% in mineral oil, 0.82 g, 20.6 mmol) in 
THF (15 mL) was added di-t-butyl 2-methylmalonate intermediate (2.37 g, 10.3 
mmol) dropwise and the solution was stirred for 10 minutes at rt.  To the reaction 
mixture, 2-bromoethyl acetate (2.84 mL, 25.8 mmol) was added dropwise at 0°C.  
The solution was allowed to warm to rt and react for 4 h.  The reaction was 
quenched with saturated NH4Cl (10 mL) at 0 °C, phases were separated, and 
aqueous phase was extracted with EtOAc (2 x 10 mL).  The combined organic 
phases were dried over MgSO4 and concentrated.  The residue was purified by 
flash chromatography on silica gel (5→20% EtOAc in hexanes) to afford the 
acetyl methylmalonate intermediate as a colorless oil (2.43 g, 75% yield). 1H 
NMR (300 MHz, CDCl3) δ 4.09 (t, J = 7.2 Hz, 2H), 2.08 (t, J = 7.2 Hz, 2H), 2.00 
(s, 3H), 1.46 (s, 18H), 1.32 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 171.1, 171.0, 
81.4, 60.9, 53.1, 33.9, 27.8, 20.9, 19.9; IR (neat) cm-1 3004, 1723, 1641, 1456, 
1392, 1367, 1237, 1119, 846; HRMS (C16H28O6, ESI): calculated 339.1783 
[M+Na]+1, found 339.1786. 
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     5.2.3 Compound 21a 
 
 
 
 
Figure 34.  Compound 21a 
 
 
To a solution of the acetyl methylmalonate intermediate (0.45 g, 1.42 
mmol) in MeOH (7.0 mL) was added K2CO3 (0.90 g) and the solution was stirred 
for 1 h at rt.  The reaction mixture was diluted with CH2Cl2 and was extracted with 
CH2Cl2 (2 x 15 mL) and H2O (1 x 10 mL).  The organic layer was dried over 
MgSO4 and concentrated. The residue was purified by flash chromatography on 
silica gel (20→40% EtOAc in hexanes with 0.1% TEA) to afford compound 21a 
as a colorless oil (0.26 g, 78% yield). 1H NMR (300 MHz, CDCl3) δ 3.69 (t, J = 
6.3 Hz, 2H), 2.73 (bs, 1H), 2.07 (t, J = 6.3 Hz , 2H), 1.47 (s, 18 H), 1.39 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 171.9, 81.4, 58.8, 53.6, 38.1, 27.8, 20.1; IR (neat) 
cm-1 3440, 2974, 2934, 1723, 1456, 1367, 1156, 1113, 847; HRMS (C14H26O5, 
ESI): calculated 297.1677 [M+Na]+1, found 297.1667. 
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     5.2.4 Compound 22a 
 
 
 
 
Figure 35. Compound 22a 
 
 
To a solution of acid (S)-14 (35 mg, 0.05 mmol) in CH2Cl2 (5 mL) was 
added compound 21b (258 mg, 0.94 mmol) and the solution was stirred for 5 d at 
rt.  The reaction was extracted with EtOAc (2 x 10 mL) and H2O (1 x 10 mL). The 
organic phase was dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (10→20% EtOAc in hexanes) to 
afford compound 22a as a white crystal (184 mg, 97% yield). 1H NMR (300 MHz, 
CDCl3) δ 4.35 (m, 2H), 2.64 (m, 1H), 2.13 (m, 1H), 1.46 (s, 12H); 
13C NMR (126 
MHz, CDCl3) δ 176.4, 169.5, 83.0, 65.9, 50.6, 35.2, 27.8, 20.1; IR (neat) cm
-1 
2980, 1735, 1448, 1372, 1235, 1043; HRMS (C10H16O4, ESI): calculated 
223.0946 [M+Na]+1, found 223.0934, [α]D
23 = - 3.6° (c =0.5, CHCl3).   
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5.3 Synthesis of Compound 22b 
     5.3.1 Allyl malonate intermediate 
 
 
 
 
Figure 36.  Allyl malonate Intermediate 
 
 
To a solution of sodium hydride (60% in mineral oil, 0.13 g, 3.13 mmol) in 
THF (7 mL) was added di-t-butyl malonate (0.68 g, 3.13 mmol) dropwise and the 
solution was stirred for 10 minutes at rt.  To the reaction mixture, allyl bromide 
(0.27 mL, 3.13 mmol) was added dropwise at 0°C.  The solution was allowed to 
warm to rt and stir for 21 h.  The reaction was quenched with saturated NH4Cl (5 
mL) at 0 °C, phases were separated, and the aqueous phase was extracted with 
EtOAc (2 x 10 mL).  The combined organic phases were dried over MgSO4 and 
concentrated.  The residue was purified by flash chromatography on silica gel 
(5→10% EtOAc in hexanes) to afford the allyl malonate intermediate as a 
colorless oil (0.66 g, 82% yield). 1H NMR (500 MHz, CDCl3) δ 5.76 (m, 1H), 5.08 
(m, 2H), 3.20 (t, J = 7.6 Hz, 1H), 2.54 (m, 2H), 1.46 (s, 18H); 13C NMR (126 MHz, 
CDCl3) δ 168.4, 134.6, 117.1, 81.5, 53.5, 32.9, 28.0; IR (neat) cm
-1 2979, 1726, 
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1643, 1456, 1367, 1135, 917, 846; HRMS (C14H24O4, ESI): calculated 279.1572 
[M+Na]+1, found 279.1556. 
 5.3.2 Compound 21b 
 
 
 
 
Figure 37.  Compound 21b 
 
 
To a solution of the allyl malonate intermediate (0.66 g, 2.57 mmol) in 3:1 
dioxane/H2O (7 mL) was added 2,6-lutidine (0.60 mL, 5.14 mmol), OsO4 (2.5% 
wt. % in tert-butanol, 0.51 mL, 0.05 mmol) and NaIO4 (2.2 g, 10.3 mmol) and the 
solution was stirred for 2 h at rt.  The reaction mixture was vacuum filtered 
through a pad of Celite and the filtrate was extracted with CH2Cl2 (1 x 10 mL) and 
H2O (1 x 10 mL).  The organic layer was washed with brine (5 mL) and dried over 
MgSO4.  The solution was concentrated to yield the crude aldehyde diester 
intermediate as a clear yellow oil (0.51 g).  
The crude aldehyde diester intermediate (0.51 g, 2.00 mmol) was 
dissolved in MeOH (4 mL) and to it was added NaBH4 (0.29 g, 8.00 mmol) in 
MeOH (4 mL) at 0 °C.  After stirring for 1 h at 0 °C, the reaction was quenched 
with 1 M HCl at 0 °C and partially concentrated.  The reaction mixture was 
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extracted with CH2Cl2 (2 x 10 mL) and H2O (1 x 10 mL).  The organic layer was 
dried over MgSO4 and concentrated. The residue was purified by flash 
chromatography on silica gel (20→40% EtOAc in hexanes with 0.1% TEA) to 
afford compound 21b as a colorless oil (0.28 g, 54% yield). 1H NMR (500 MHz, 
CDCl3) δ 3.71 (m, 2H), 3.34 (t, J = 15.6 Hz, 1H), 2.07 (m, 2 H), 1.96 (bs, 1H), 
1.45 (s, 18H); 13C NMR (126 MHz, CDCl3) δ 169.1, 81.8, 60.7, 51.3, 31.5, 28.0; 
IR (neat) cm-1 3441, 2977, 2933, 1723, 1456, 1367, 1137, 843; HRMS (C13H24O5, 
ESI): calculated 283.1521 [M+Na]+1, found 283.1523. 
     5.3.3 Compound 22b 
 
 
 
 
Figure 38.  Compound 22b 
 
 
To a solution of acid (S)-14 (41 mg, 0.05 mmol) in CH2Cl2 (6 mL) was 
added compound 21b (282 mg, 1.08 mmol) and the solution was stirred for 72 h 
at 5 °C.  The reaction was extracted using EtOAc (2 x 10 mL) and H2O (1 x 10 
mL). The organic phase was dried over MgSO4 and concentrated.  The residue 
was purified by flash chromatography on silica gel (10→20% EtOAc in hexanes) 
to afford compound 22b as a colorless oil (188 mg, 93% yield). 1H NMR (500 
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MHz, CDCl3) δ 4.43 (m, 1H) 4.30 (m, 1H), 3.42 (m, 1H), 2.59 (m, 1H), 2.46 (m, 
1H), 1.48 (s, 9 H); 13C NMR (126 MHz, CDCl3) δ 172.9, 166.9, 83.1, 67.3, 47.0, 
27.9, 26.5; IR (neat) cm-1 2980, 1772, 1725, 1369, 1138, 1016; HRMS (C9H14O4, 
ESI): calculated 185.0813, [M-H]-1, found 185.0807; [α]D
23 = +3.6° (c = 2.8, 
CHCl3). 
5.4 Synthesis of Compound 22c 
     5.4.1 Di-t-butyl 2-ethylmalonate intermediate 
 
 
 
 
Figure 39.  Di-t-butyl 2-ethylmalonate Intermediate 
 
 
To a solution of sodium hydride (60% in mineral oil, 93 mg, 2.32 mmol) in 
THF (7 mL) was added di-t-butyl malonate dropwise (0.5 g, 2.32 mmol) and the 
solution was stirred for 10 minutes at rt.  To the reaction mixture, iodoethane 
(0.18 mL, 2.32 mmol) was added dropwise and the solution was stirred for 22 h 
at rt.  The reaction was quenched with saturated NH4Cl (6 mL) at 0 °C, phases 
were separated, and aqueous phase was extracted EtOAc (2 x 15 mL).  The 
combined organic phases were dried over MgSO4 and concentrated.  The 
residue was purified by flash chromatography on silica gel (5→15% EtOAc in 
hexanes) to afford the di-t-butyl 2-ethylmalonate intermediate as a white crystal 
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(0.44 g, 78% yield).  1H NMR (400 MHz, CDCl3) δ 3.02 (t, J = 7.3 Hz, 1H), 1.79 
(m, 2H), 1.41 (s, 18H), (s, 18 H), 0.91 (t, J = 7.3, 3H); 13C NMR (100 MHz, 
CDCl3) δ 168.9, 81.0, 55.4, 27.8, 21.9, 11.7; IR (neat) cm
-1 2973, 1724, 1458, 
1365, 1134, 850; HRMS (C13H24O4, ESI) calculated 267.1572 [M+Na]
+1, found 
267.1560. 
     5.4.2 Acetyl ethylmalonate intermediate 
 
 
 
 
Figure 40. Acetyl Ethylmalonate Intermediate 
 
 
To a solution of sodium hydride (60% in mineral oil, 0.14 g, 3.6 mmol) in 
THF (7 mL) was added di-t-butyl 2-ethylmalonate intermediate (0.44 g, 1.8 mmol) 
dropwise and the solution was stirred for 10 minutes at rt.  To the reaction 
mixture, 2-bromoethyl acetate (0.5 mL, 4.5 mmol) was added dropwise at 0°C.  
The solution was allowed to warm to rt and react for 23 h.  The reaction was 
quenched with saturated NH4Cl (5 mL) at 0 °C, phases were separated, and 
aqueous phase was extracted with EtOAc (2 x 10 mL).  The combined organic 
phases were dried over MgSO4 and concentrated.  The residue was purified by 
flash chromatography on silica gel (5→10% EtOAc in hexanes) to afford the 
acetyl ethylmalonate intermediate as a white crystal (0.45 g, 76% yield). 1H NMR 
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(500 MHz, CDCl3) δ 4.11 (t, J = 7.2 Hz, 2H), 2.13 (t, J = 7.2 Hz, 2H), 2.00 (s, 3H), 
1.81 (q, J = 7.4 Hz, 2H), 1.44 (s, 18H), 0.82 (t, J = 7.4, 3H); 13C NMR (126 MHz, 
CDCl3) δ 171.0, 170.5, 81.3, 60.8, 57.3, 30.0, 28.0, 25.1, 21.0, 8.2; IR (neat) cm
-1 
2942, 1740, 1723, 1641, 1457, 1366, 1140, 1118, 848; HRMS (C17H30O6, ESI): 
calculated 353.1940 [M+Na]+1, found 353.1942. 
     5.4.3 Compound 21c 
 
 
 
 
Figure 41. Compound 21c 
 
 
To a solution of the acetyl ethylmalonate intermediate (0.41 g, 1.23 mmol) 
in methanol (6 mL) was added K2CO3 (0.82 g) and the solution was stirred for 1 h 
at rt.  The reaction mixture was diluted with CH2Cl2 and was extracted with 
CH2Cl2 (2 x 15 mL) and H2O (1 x 10 mL).  The organic layer was dried over 
MgSO4 and concentrated to afford compound 21c as a white crystal (0.31 g, 87% 
yield). 1H NMR (500 MHz, CDCl3) δ 3.65 (m, 2H), 2.07 (t, J = 6.6 Hz , 2H), 1.88 
(m, q, J = 7.5 Hz, 2H), 1.44 (s, 18 H), 0.83 (t, J = 7.6 Hz, 3H); 13C NMR (126 
MHz, CDCl3) δ 171.4, 81.3, 59.1, 57.7, 34.7, 27.9, 25.9, 8.6; IR (neat) cm
-1 3434, 
2975, 2934, 1745, 1474, 1365, 1154, 1117, 851; HRMS (C15H28O5, ESI): 
calculated 311.1834 [M+Na]+1, found 311.1835.
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     5.4.4 Compound 22c 
 
 
 
 
Figure 42. Compound 22c 
 
 
To a solution of acid (S)-14 (18 mg, 0.02 mmol) in CH2Cl2 (5 mL) was 
added compound 21c (136 mg, 0.47 mmol) and the solution was stirred for 6 d at 
rt.  The reaction was extracted with EtOAc (2 x 10 mL) and H2O (1 x 10 mL). The 
organic phase was dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (10→20% EtOAc in hexanes) to 
afford compound 22c as a white crystal (94 mg, 93% yield). 1H NMR (500 MHz, 
CDCl3) δ 4.32 (m, 2H), 2.63 (m, 1H), 2.21 (m, 1H), 2.04 (m, 1H), 1.81 (m, 1H), 
1.46 (s, 9 H), 0.95 (t, J = 7.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 175.3, 168.7, 
82.9, 66.1, 55.4, 31.3, 27.9, 27.1, 9.1; IR (neat) cm-1 2979, 1741, 1466, 1370, 
1236, 1043; HRMS (C11H18O4, ESI): calculated 237.1102 [M+Na]
+1, found 
237.1105; [α]D
23 = +1.6° (c= 2.2, CHCl3).
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5.5 Synthesis of Compound 22d 
     5.5.1 Di-t-butyl 2-isopropylmalonate intermediate 
 
 
 
 
Figure 43. Di-t-butyl 2-isopropylmalonate Intermediate 
 
 
To a solution of sodium hydride (60% in mineral oil, 0.09 g, 2.32 mmol) in 
THF (7 mL) was added di-t-butyl malonate dropwise (0.5 g, 2.32 mmol) and the 
solution was stirred for 10 minutes at rt.  To the reaction mixture, 2-iodopropane 
(0.23 mL, 2.32 mmol) was added dropwise and the solution was stirred for 22 h 
at rt.  The reaction was quenched with saturated NH4Cl (6 mL) at 0 °C, phases 
were separated, and aqueous phase was extracted EtOAc (2 x 15 mL).  The 
combined organic phases were dried over MgSO4 and concentrated.  The 
residue was purified by flash chromatography on silica gel (5→10% EtOAc in 
hexanes) to afford the di-t-butyl 2-isopropylmalonate intermediate as a colorless 
oil (0.4 g, 67% yield). 1H NMR (500 MHz, CDCl3) δ 2.87 (d, J = 8.9 Hz, 1H), 2.27 
(m, 1H), 1.44 (s, 18H), 0.97 (d, J = 6.7, 6H); 13C NMR (126 MHz, CDCl3) δ 168.3, 
81.2, 61.1, 28.4, 28.0, 20.4; IR (neat) cm-1 2967, 1721, 1473, 1365, 1118, 981; 
HRMS (C14H26O4, ESI): calculated 281.1728 [M+Na]
+1, found 281.1717.
52 
 
     5.5.2 Compound 21d 
 
 
 
Figure 44. Compound 21d 
 
 
To a solution of sodium hydride (60% in mineral oil, 0.11 g, 2.76 mmol) in 
THF (8 mL) was added di-t-butyl 2-ethylmalonate intermediate (0.36 g, 1.38 
mmol) dropwise and the solution was stirred for 10 minutes at rt.  To the reaction 
mixture, allyl bromide (0.6 mL, 6.9 mmol) was added dropwise at 0°C.  The 
solution was allowed to warm to rt and react for 26 h.  The reaction was 
quenched with saturated NH4Cl (10 mL) at 0 °C, phases were separated, and 
aqueous phase was extracted with EtOAc (2 x 10 mL).  The combined organic 
phases were dried over MgSO4 and concentrated.  The residue was purified by 
flash chromatography on silica gel (5→20% EtOAc in hexanes) to afford the allyl 
isopropylmalonate intermediate as a colorless oil (0.372 g, 90% yield). 1H NMR 
(400 MHz, CDCl3) δ 5.70 (m, 1H), 5.00 (m, 2H), 2.50 (d, J = 7.3 Hz, 2H), 2.20 (m, 
1H), 1.42 (s, 18H), 0.95 (d, J = 6.9 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 168.9, 
133.7, 117.7, 80.9, 61.6, 37.8, 31.1, 27.9, 18.5.
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To a solution of the allyl isopropylmalonate intermediate (0.27 g, 0.9 
mmol) in 3:1 dioxane/H2O (6 mL) was added 2,6-lutidine (0.21 mL, 1.8 mmol), 
OsO4 (2.5% wt. % in tert-butanol, 18 mL, 0.018 mmol) and NaIO4 (0.77 g, 77 
mmol) and the solution was stirred for 3 h at rt.  The reaction mixture was filtered 
through a pad of Celite and was extracted with CH2Cl2 (2 x 15 mL) and H2O (1 x 
10 mL).  The organic layer was washed with brine (5 mL) and dried over MgSO4.  
The solution was concentrated to yield the crude aldehyde diester intermediate 
as a clear yellow oil (0.19 g).  
The crude aldehyde diester intermediate (0.19 g, 0.65 mmol) was 
dissolved in MeOH (4 mL) and to it was added NaBH4 (0.01 g, 2.6 mmol) at 0 °C.  
After stirring for 1 h at 0 °C, the reaction was quenched with 1 M HCl at 0 °C and 
reaction mixture was partially concentrated.  The reaction mixture was extracted 
with CH2Cl2 (2 x 10 mL) and H2O (1 x 10 mL).  The organic layer was dried over 
MgSO4 and concentrated. The residue was purified by flash chromatography on 
silica gel (20→40% EtOAc in hexanes with 0.1% TEA) to afford compound 21d 
as a colorless oil (0.09 g, 46% yield). 1H NMR (500 MHz, CDCl3) δ 3.74 (m, 2H), 
2.23 (m, 1H), 2.01 (t, J = 6.5 Hz, 2H), 1.46 (s, 18 H), 0.96 (d, J = 6.9 Hz, 6H); 13C 
NMR (126 MHz, CDCl3) δ 170.6, 82.1, 61.5, 59.5, 36.3, 33.3, 28.3, 18.2; IR 
(neat) cm-1 3004,  2936, 2356, 1712, 1475, 1365, 1147, 1066, 852; HRMS 
(C16H30O5, ESI): calculated 325.1990 [M+Na]
+1, found 325.2001.
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      5.5.3 Compound 22d 
 
 
 
 
Figure 45. Compound 22d 
 
 
To a solution of acid (R)-14 (7.2 mg, 0.01 mmol) in CH2Cl2 (2.5 mL) was 
added compound 21d (58.1 mg, 0.19 mmol) and the solution was stirred for 9 d 
at 32 °C.  The reaction was extracted with EtOAc (2 x 10 mL) and H2O (1 x 10 
mL). The organic phase was dried over MgSO4 and concentrated.  The residue 
was purified by flash chromatography on silica gel (10→20% EtOAc in hexanes) 
to afford compound 22d as a white crystal (39.2 mg, 89% yield). 1H NMR (400 
MHz, CDCl3) δ 4.32 (m, 2H), 2.61 (m, 2H), 2.17 (m, 1H), 1.47 (s, 9 H), 0.89 (m, 
6H); 13C NMR (100 MHz, CDCl3) δ 174.5, 167.9, 82.8, 66.2, 59.8, 31.4, 27.7, 
26.3, 17.9, 17.7; IR (neat) cm-1 2970, 1734, 1414, 1383, 1201, 1044; HRMS 
(C12H20O4, ESI): calculated 251.1259 [M+Na]
+1, found 251.1259. [α]D
23 = -5.6° (c 
= 1.1, CHCl3).
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5.6 Synthesis of Compound 22e 
 
 
     5.6.1 Di-t-butyl 2-(2-acetoxyethyl)-2-allylmalonate intermediate 
 
 
 
 
Figure 46. Di-t-butyl 2-(2-acetoxyethyl)-2-allylmalonate Intermediate 
 
 
To a solution of sodium hydride (60% in mineral oil, 54 mg, 1.36 mmol) in 
THF (7 mL) was added di-t-butyl 2-allylmalonate dropwise (0.29 g, 1.13 mmol) 
and the solution was stirred for 10 minutes at rt. To the reaction mixture, 2-
bromoethyl acetate (0.14 mL, 1.24 mmol) was added dropwise at 0°C.  The 
solution was allowed to warm to rt and react for 47 h.  The reaction was 
quenched with saturated NH4Cl (6 mL) at 0 °C, phases were separated, and 
aqueous phase was extracted EtOAc (2 x 15 mL).  The combined organic 
phases were dried over MgSO4 and concentrated.  The residue was purified by 
flash chromatography on silica gel (10→15% EtOAc in hexanes) to afford the di-
t-butyl 2-(2-acetoxyethyl)-2-allylmalonate intermediate as a colorless oil (0.14 g, 
35% yield). 1H NMR (500 MHz, CDCl3) δ 5.61 (m, 1H), 5.11 (m, 2H), 4.12 (t, J = 
7.2 Hz, 2H), 2.62 (d, J = 7.6 Hz, 2H), 2.14 (t, J = 7.2 Hz, 2H), 2.01 (s, 3H), 1.45 
(s, 18H); 13C NMR (126 MHz, CDCl3) δ 171.0, 169.9, 132.4, 119.3, 81.7, 60.7, 
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56.4, 37.1, 30.7, 27.9, 21.1; IR (neat) cm-1 2937, 1739, 1723, 1477, 1366, 1221, 
1139, 844; HRMS (C18H30O6, ESI): calculated 365.1940 [M+Na]
+1, 365.1945. 
     5.6.2 Compound 21e 
 
 
 
 
Figure 47. Compound 21e 
 
 
To a solution of the di-t-butyl 2-(2-acetoxyethyl)-2-allylmalonate 
intermediate (59 mg, 0.17 mmol) in MeOH (2 mL) was added K2CO3 (117 mg) 
and the solution was stirred for 1 h at rt.  The reaction mixture was diluted with 
CH2Cl2 (15 mL) and extracted with H2O (1 x 10 mL).  The organic layer was 
washed with brine (5 mL) and dried over MgSO4.  The solution was concentrated 
to yield compound 21e as a colorless oil (38 mg, 74% yield). 1H NMR (500 MHz, 
CDCl3) δ 5.63 (m, 1H), 5.08 (m, 2H), 3.67 (t, J = 6.6 Hz, 2H), 2.58 (d, J = 7.4 Hz, 
2H), 2.05 (t, J = 6.6 Hz, 2H), 1.43 (s, 18 H); 13C NMR (126 MHz, CDCl3) δ 170.1, 
132.4, 118.8, 81.6, 59.0, 56.9, 37.8, 35.3, 27.3; IR (neat) cm-1 3010, 2943, 1736, 
1477, 1364, 1260, 1142, 1074;  HRMS (C16H28O5, ESI): calculated 323.1834 
[M+Na]+1, found  323.1826. 
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     5.6.3 Compound 22e 
 
 
 
 
Figure 48.  Compound 22e 
 
 
To a solution of acid (R)-14 (3.2 mg, 0.004 mmol) in CH2Cl2 (2 mL) was 
added compound 21e (26 mg, 0.08 mmol) and the solution was stirred for 8 d at 
rt.  The reaction was extracted with EtOAc (2 x 10 mL) and H2O (1 x 10 mL). The 
organic phase was dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (10→20% EtOAc in hexanes) to 
afford compound 22e as a white crystal (18 mg, 95% yield). 1H NMR (400 MHz, 
CDCl3) δ 5.72 (m, 1H), 5.22 (m, 2H), 4.31 (m, 2H), 2.73 (m, 1H), 2.51 (m, 2 H), 
2.33 (m, 1H), 1.45 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 174.9, 168.4, 132.2, 
120.2, 83.2, 66.7, 54.4, 37.9, 31.1, 27.9; IR (neat) cm-1 2949, 1772, 1349, 1286, 
1141, 1066; HRMS (C12H18O4, ESI): calculated 249.1102 [M+Na]
+1,  found 
249.1093, [α]D
23 = -4.7° (c= 0.5, CHCl3).
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5.7 Synthesis of Compound 22f 
     5.7.1 Allyl benzylmalonate intermediate 
 
 
 
Figure 49. Allyl Benzyl Malonate Intermediate 
 
 
To a solution of sodium hydride (60% in mineral oil, 0.13 g, 3.13 mmol) in 
THF (8 mL) was added di-t-butyl malonate dropwise (0.68 g, 3.13 mmol) and the 
solution was stirred for 10 minutes at rt.  To the reaction mixture, benzylbromide 
(0.37 mL, 3.13 mmol) was added dropwise and the solution was stirred for 24 h 
under reflux.  The reaction was quenched with saturated NH4Cl (6 mL) at 0 °C, 
phases were separated, and aqueous phase was extracted EtOAc (2 x 15 mL).  
The combined organic phases were dried over MgSO4 and concentrated to yield 
di-t-butyl 2-benzylmalonate intermediate.  
To a solution of sodium hydride (60% in mineral oil, 0.20 g, 5.0 mmol) in 
THF (8 mL) was added di-t-butyl 2-benzylmalonate intermediate (0.77 g, 2.5 
mmol) dropwise and the solution was stirred for 15 minutes at rt.  To the reaction 
mixture, allyl bromide (0.54 mL, 6.25 mmol) was added dropwise at 0°C.  The 
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solution was allowed to warm to rt and react for 47 h.  The reaction was 
quenched with saturated NH4Cl (10 mL) at 0 °C, phases were separated, and 
aqueous phase was extracted with EtOAc (2 x 10 mL).  The combined organic 
phases were dried over MgSO4 and concentrated. The residue was purified by 
flash chromatography on silica gel (515% EtOAc in hexanes) to afford the allyl 
benzylmalonate intermediate as a colorless oil (0.77 g, 89% yield). 1H NMR (500 
MHz, CDCl3) δ 7.23 (m, 5H), 5.77 (m, 1H), 5.14 (m, 2H), 3.15 (s, 2H), 2.49 (d, J = 
7.4 Hz, 2H), 1.45 (s, 18 H); 13C NMR (126 MHz, CDCl3) δ 170.1, 136.6, 133.1, 
130.4, 128.2, 126.9, 119.1, 81.6, 59.2, 37.6, 36.5, 28.1; IR (neat) cm-1 3324, 
2978, 2963, 1758, 1471, 1350, 1332, 1140, 1045, 879; HRMS (C21H30O5, ESI): 
calculated 385.1990 [M+Na]+1, found 385.1988. 
     5.7.2 Compound 21f 
 
 
 
Figure 50. Compound 21f 
 
 
To a solution of the allyl benzylmalonate intermediate (0.93 g, 2.75 mmol) 
in 3:1 dioxane/H2O (7 mL) was added 2,6-lutidine (0.64 mL, 5.5 mmol), OsO4 
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(2.5% wt. in t-butanol, 0.44 mL, 0.06 mmol) and NaIO4 (2.35 g, 11.0 mmol) and 
the solution was stirred for 2 h at rt.  The reaction mixture was filtered through a 
pad of Celite and was extracted with CH2Cl2 (2 x 15 mL) and H2O (1 x 10 mL).  
The organic layer was washed with brine (5 mL) and dried over MgSO4.  The 
solution was concentrated to yield the crude aldehyde diester intermediate as a 
clear yellow oil (0.57 g).  
The crude aldehyde diester intermediate (0.57 g, 1.63 mmol) was 
dissolved in MeOH (10 mL) and to it was added NaBH4 (0.25 g, 6.52 mmol) at 0 
°C.  After stirring for 1 h at 0 °C, the reaction was quenched with 1 M HCl at 0 °C 
and reaction mixture was partially concentrated.  The reaction mixture was 
extracted with CH2Cl2 (2 x 10 mL) and H2O (1 x 10 mL).  The organic layer was 
dried over MgSO4 and concentrated. The residue was purified by flash 
chromatography on silica gel (20→40% EtOAc in hexanes with 0.1% TEA) to 
afford compound 21f as a colorless oil (0.24 g, 42% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.26 (m, 5H), 3.75 (t, J = 6.6 Hz, 2H), 3.21 (s, 2H), 2.00 (t, J = 6.6 Hz , 
2H), 1.47 (s, 18 H); 13C NMR (126 MHz, CDCl3) δ 170.8, 136.4 130.3, 128.2, 
126.9, 82.1, 59.2, 58.2, 39.1, 35.5, 28.0; IR (neat) cm-1 3321, 2971, 2963, 1758, 
1471, 1330, 1116, 1045, 879; HRMS (C20H30O5, ESI): calculated 373.1990 
[M+Na]+1, found 373.1987. 
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     5.7.3 Compound 22f 
 
 
 
 
Figure 51. Compound 22f 
 
 
To a solution of acid (S)-14 (15.6 mg, 0.021 mmol) in CH2Cl2 (5 mL) was 
added compound 21f (146 mg, 0.42 mmol) and the solution was stirred for 7 d at 
32 °C.  The reaction was extracted with EtOAc (2 x 10 mL) and H2O (1 x 10 mL). 
The organic phase was dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (10→20% EtOAc in hexanes) to 
afford compound 22f as a colorless oil (77 mg, 67% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.25 (m, 5H), 4.25 (m, 1H), 3.85 (m, 1H), 3.25 (m, 2H), 2.54 (m, 1H), 
2.25 (m, 1H), 1.47 (s, 9 H); 13C NMR (126 MHz, CDCl3) δ 175.3, 169.6, 135.7, 
130.2, 128.7, 127.3, 83.3, 66.2, 56.1, 38.9, 30.6, 27.9; IR (neat) cm-1 2979, 2360, 
1771, 1721, 1454, 1368, 1145, 1029; HRMS (C16H20O4, ESI): calculated 
299.1259 [M+Na]+1, found 299.1261; [α]D
23 = +25.1° (c= 1.1, CHCl3).
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5.8 Synthesis of Compound 22g 
     5.8.1 Compound 21g 
 
 
 
 
Figure 52. Compound 21g 
 
 
To a solution of sodium hydride (60% in mineral oil, 1.5 g, 38.2 mmol) in 
THF (10 mL) was added di-t-butyl 2-methylmalonate intermediate dropwise (4.4 
g, 19.1 mmol) and the solution was stirred for 10 minutes at rt.  To the reaction 
mixture, allyl bromide (4.2 mL, 47.8 mmol) was added dropwise and the solution 
was stirred for 24 h at rt.  The reaction was quenched with saturated NH4Cl (7 
mL) at 0 °C, phases were separated, and aqueous phase was extracted EtOAc 
(2 x 15 mL).  The combined organic phases were dried over MgSO4 and 
concentrated to afford the di-t-butyl 2-allyl-2-methylmalonate intermediate).  
The BH3-THF (1M in THF, 0.74 mmol) was diluted with THF (0.11 mL). To 
the solution was added di-t-butyl 2-allyl-2-methylmalonate intermediate (0.4 g) at 
0 °C and allowed to warm up to rt.  After 2.5 h, a NaOH solution (3 M, 0.89 mL) 
was added followed by hydrogen peroxide (30 wt % in water, 0.3 mL, 2.87 mmol) 
at 0 °C.  The reaction mixture stirred at 50 °C for overnight.  The reaction mixture 
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was extracted with Et2O (2 x 10 mL) and H2O (1 x 10mL).  The organic layer was 
dried over MgSO4 and concentrated.  The residue was purified by flash 
chromatography on silica gel (20→40% EtOAc in hexanes with 0.1% TEA) to 
afford compound 21g as a colorless oil (0.13 g, 31% yield). 1H NMR (500 MHz, 
CDCl3) δ 3.62 (m, 2H), 1.79 (m, 2H), 1.51 (m, 2H), 1.42 (s, 18H), 1.29 (s, 3H); 
13C NMR (126 MHz, CDCl3) δ 171.8, 81.1, 62.9, 54.3, 31.6, 27.9, 19.9; IR (neat) 
cm-1 3442, 2970, 2929, 1720, 1457, 1366, 1150, 1112, 851; HRMS (C15H28O5, 
ESI): calculated 311.1834 [M+Na]+1, found 311.1825. 
     5.8.2 Compound 22g 
 
 
 
 
Figure 53. Compound 22g 
 
 
To a solution of acid 14 (3.0 mg, 0.004 mmol) in CH2Cl2 (2 mL) was added 
compound 21g (46.2 mg, 0.16 mmol) and the solution was stirred for 5 d at rt.  
The reaction was extracted with EtOAc (2 x 10 mL) and H2O (1 x 10 mL). The 
organic phase was dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (10→20% EtOAc in hexanes) to 
afford compound 22g as a colorless oil (29.1 mg, 85% yield). 1H NMR (500 MHz, 
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CDCl3) δ 4.32 (m, 1H), 2.42 (m, 1H), 1.91 (m, 2H), 1.63 (m, 1H), 1.46 (s, 12H); 
13C NMR (126 MHz, CDCl3) δ 171.5, 171.1, 82.7, 68.7, 51.1, 30.8, 27.8, 23.1, 
20.5; IR (neat) cm-1; 2983, 1730, 1446, 1370, 1229, 1042; HRMS (C11H18O4, 
ESI): calculated 237.1102 [M+Na]+1, found 237.1095;  [α]D
23: +14.1° (c= 1.0, 
CHCl3). 
5.9 Scale Up Synthesis #1 of Compound 22a 
 
 
 
 
Figure 54. Scale Up Synthesis #1 of Compound 22a 
 
 
To a solution of acid (S)-14 (0.2 g, 0.35 mmol) in CH2Cl2 (10 mL) was 
added compound 21b (1.9 g, 6.9 mmol) and the solution was stirred for 5 d at rt.  
The reaction was extracted with EtOAc (2 x 10 mL) and H2O (1 x 10 mL). The 
organic phase was dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (10→20% EtOAc in hexanes) to 
afford compound 22a as a white crystal (1.3 g, 95% yield). 
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5.10 Scale Up Synthesis #2 of Compound 22a 
     5.10.1 Methylmalonate intermediate 
 
 
 
 
Figure 55.  Scale Up of Methylmalonate Intermediate 
 
 
To a solution of methyl malonic acid (12.0 g, 101.6 mmol) in diethyl ether 
(50 mL), was added 4-(Dimethylamino)pyridine (1.2 g, 9.0 mmol, 0.1 equiv), tert-
butyl alcohol (150 mL),  and solid di-tert-butyl dicarbonate (48.0 g, 220 mmol, 2.2 
equiv).  The heterogeneous slurry was stirred at room temperature for 48 h, after 
which time the reaction mixture became a clear pale yellow mixture.  The 
reaction mixture was then diluted by addition of diethyl ether (150 mL), and was 
extracted with water (2 x 50 mL) and HCl (1.0 M, 2 x 50 mL). The organic layer 
was dried over MgSO4, gravity filtered using coarse filter paper, rinsed with 
diethyl ether (20 mL), and concentrated to give an oil, which was dissolved in 200 
mL of hexanes and ethyl acetate (10:1) and passed through a plug of silica gel 
using a 60-mL medium fritted filter funnel. The colorless filtrate was concentrated 
to afford the di-t-butyl 2-methylmalonate intermediate as a colorless oil (23.1 g, 
98% yield). 
66 
 
     5.10.2 Compound 21a 
 
 
 
 
Figure 56. Scale Up of Compound 21a 
 
 
Tetrahydrofuran (100mL) was added via a syringe and the reaction flask 
was cooled with an ice-water bath.  After stirring 15 min, NaH (3.13 g, 78.2 mmol, 
1.2 equiv) was added and the slurry was stirred for an additional 15 min.  Di-tert-
butyl-2-methylmalonate (15.0 g, 65.2 mmol) was dissolved in tetrahydrofuran (30 
mL) and this solution was cannulated into to the sodium hydride slurry over 15 
min.  After 30 min 2-bromoethyl acetate (8.6 mL, 78.2 mmol, 1.2 equiv) was 
added drop wise via a syringe over a period of 5 min.  The reaction mixture was 
allowed to slowly warm to room temperature.  TLC analysis indicated 
consumption of the di-tert-butyl-2-methylmalonate after 16 h.  The reaction flask 
was cooled in an ice-water bath for 15 min, and a solution of saturated NH4Cl 
solution (10 mL) was added dropwise via syringe.  The mixture was diluted with 
diethyl ether (300 mL) and extracted with water (2 x 50 mL) and saturated NaCl 
solution (50 mL), dried over MgSO4, gravity filtered using coarse filter paper, 
rinsed with diethyl ether (20 mL), and concentrated to give a pale yellow oil which 
was dissolved in methanol (50 mL).  The solution was transferred to an oven 
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dried 500-mL two-necked round-bottom flask and was cooled to 10 °C using a 
saturated NaCl solution/ice bath and K2CO3 (9.0 g, 65.2 mmol) was added in 
portions.  After 2 h, the reaction mixture was diluted with diethyl ether (200 mL) 
and deionized water (50 mL) was added drop wise.  The reaction was extracted 
with hexanes (100 mL) and water (3 x 50 mL).  The organic layer was washed 
with saturated NaCl solution (50 mL), dried over MgSO4, gravity filtered using 
coarse filter paper, rinsed with diethyl ether (20 mL), and concentrated to give a 
light yellow oil.  The oil was dissolved into hexanes (100 mL) and the flask was 
cooled with an ice-water bath for one h to yield a layer of white solids.  The solids 
were broken via a spatula and collected via vacuum filtration into a 100 mL 
ceramic Buchner funnel equipped with filter paper of moderate porosity and 
washed with ice-cold hexanes (25 mL). A second crop of solids were obtained 
after the filtrate was concentrated under vacuum and the residue was dissolved 
in hexanes (20 mL), cooled with an ice water bath for 2 h and filtered as before to 
yield compound 21a as a white solid (13.5 g, 76% yield).
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     5.10.3 Compound 22a 
 
 
 
 
Figure 57. Scale Up of Compound 22a 
 
 
To a solution of di-tert-butyl 2-(2-hydroxyethyl)-2-methylmalonate (8.5 g, 
31 mmol) in toluene (310 mL) was added acid (R)-14 (0.23 g, 0.31 mmol, 0.01 
equiv).  The reaction mixture was heated to 80 °C and progress of the reaction 
was monitored by TLC analysis.  TLC analysis indicated consumption of the di-
tert-butyl 2-(2-hydroxyethyl)-2-methylmalonate after 48 h.  The round bottomed 
flask was allowed to cool slowly in the oil bath to 23 °C and diluted using EtOAc 
(50 mL).  After stirring for 5 min, the reaction mixture was was extracted using 
EtOAc (250 mL) and deionized water (250 mL).  The combined EtOAc layers are 
dried over MgSO4 and gravity filtered.  The crude reaction mixture was purified 
via flash chromatography (20:1 EthOAc/hexane) to afford compound 22a as a 
white crystalline solid (5.96 g, 96% yield).
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5.11 Compound 24  
 
 
 
 
Figure 58. Compound 24 
 
 
To a solution of compound 22a (110 mg, 0.5 mmol) in THF (5.0 mL) was 
added a solution of LiAl(OtBu)3H (1.0 M in THF, 2 mL, 2.0 mmol) at -78 °C.  The 
solution was allowed to warm to rt and react for 24 h.   The reaction was 
quenched with saturated potassium sodium tartrate, phases were separated, and 
aqueous phase was extracted with EtOAc (2 x 10 mL).  The combined organic 
phases were dried over MgSO4 and concentrated.  The residue was purified by 
flash chromatography on silica gel (20→40% EtOAc in hexanes) to afford 
compound 24 as a colorless oil (94 mg, 92% yield).  1H NMR (500 MHz, CDCl3) δ 
4.23 (m, 2H), 3.48 (d, J = 8.6 Hz, 1H), 3.23 (d, J = 8.0 Hz, 1H),  2.43 (m, 1H), 
1.99 (m, 1H), 1.17 (s, 3H) 1.12 (s, 9 H); 13C NMR (126 MHz, CDCl3) δ 181.5, 
73.6, 67.3, 65.9, 43.8, 32.8, 27.0, 20.3; IR (neat) cm-1 3436, 2976, 2930, 1722, 
1456, 1367, 1146, 1103, 846; HRMS (C10H20O4, ESI): calculated 227.1259 
[M+Na]+1, found 227.1250; [α]D
23 = -0.6° (c = 1.0, CHCl3).
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5.12 Compound 25 
 
 
 
 
Figure 59. Compound 25 
 
 
To a solution of compound 22a (100 mg, 0.5 mmol) in THF (5.0 mL) was 
added benzyl amine (0.27 mL, 2.5 mmol) at rt.  The solution was allowed to react 
under reflux for 4 d.   The reaction was acidified with 1 M HCl at 0 °C and 
extracted with Et2O (2 x 10 mL) and H2O (1 x 10 mL).  The combined organic 
phases were dried over MgSO4 and concentrated.  The residue was purified by 
flash chromatography on silica gel (15→30% EtOAc in hexanes) to afford 
compound 25 as a colorless oil (90 mg, 77% yield)  1H NMR (500 MHz, CDCl3) δ 
7.27 (m, 5H), 4.44 (d, J = 5.7 Hz, 2H), 3.70 (m, 2H), 2.15 (m, 2H), 1.46 (m, 3H) 
1.44 (s, 9 H); 13C NMR (126 MHz, CDCl3) δ 174.0, 172.2, 138.1, 128.7, 127.7, 
127.5, 82.3, 59.4, 52.9, 43.6, 39.2, 27.7, 22.1; IR (neat) cm-1 3358, 2980, 2359, 
1726, 1369, 1242, 1045; HRMS (C17H25NO4, ESI): calculated 308.1861 [M+H]
+1, 
found 308.1866; [α]D
23 = -3.3° (c = 1.5, CHCl3).
71 
 
5.13 Compound 26 
 
 
 
 
Figure 60.  Compound 26 
 
 
To a solution of compound 22a (45 mg, 0.22 mmol) was added 
trifluoroacetic acid (9 mL) at rt.  The solution was allowed to react at rt overnight.  
The reaction mixture was then concentrated.  To the reaction residue was added 
NaN3 (18 mg, 0.27 mmol) and PPh3 (0.12 g, 0.44 mmol) at rt.  MeCN (10 mL) 
was then added to reaction mixture at 0 °C and stirred until homologous.  
Cl3CCN (0.08 mL, 0.44 mmol) was added at 0 °C and the solution was allowed to 
warm to rt and react for 30 hr. The reaction mixture was partially concentrated 
and the residue with dissolved in CH2Cl2 (5 mL) and extracted with CH2Cl2 (2 x 
10 mL) and H2O (1 x 10 mL).  The combined organic phases were dried over 
MgSO4 and concentrated to yield a yellow clear oil (43 mg). 
The crude acyl azide intermediate (43 mg, 0.26 mmol) was dissolved in 
THF (1.5 mL) and heated to 100 °C for 20 min in a microwave reactor.  The 
observance of an isocyanate peak (2283 cm-1) by IR spectroscopy confirmed the 
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rearrangement had occurred.  A mixture of K2CO3 (0.14 g, 1.02 mmol) in H2O 
(0.3 mL) was added to the reaction mixture and allowed to stir for 20 min. and to 
it was added benzoyl chloride (0.027mL, 0.24 mmol).  The solution was allowed 
to react overnight at rt.  The reaction was acidified with 1 M HCl and reaction 
mixture was extracted with EtOAc (2 x 10 mL) and H2O (1 x 10 mL).  The organic 
layer was dried over MgSO4 and concentrated. The residue was purified by flash 
chromatography on silica gel (30→60% Acetone in hexanes) to afford compound 
26 as a white crystal (31 mg, 56% yield). 1H NMR (500 MHz, CDCl3) δ 7.78-7.42 
(m, 5H), 6.61 (bs, 1H), 4.56 (m, 1H), 4.33 (m, 1H), 2.83 (m, 1H), 2.57 (m, 1H), 
1.63 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 177.8, 166.8, 133.5, 132.3, 130.2, 
128.8, 65.9, 56.2, 35.0, 22.3; IR (neat) cm-1 3296, 2982, 2361, 1763, 1632, 1527, 
1319, 1107, 1023, 936; HRMS (C16H30O5, ESI): calculated 325.1990 [M+Na]
+1, 
found 325.2001. [α]D
23 = +2.0° (c = 1.0, CHCl3). 
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5.14 Compound 27 
     5.14.1 Amide ester intermediate 
 
 
 
 
Figure 61. Amide Ester Intermediate 
 
 
To a solution of compound 22a (88.1 mg, 0.44 mmol) in dioxane (1.5 mL) 
was added concentrated NH4OH (5 mL) at rt.  The solution was allowed to react 
at rt overnight.  The reaction mixture was then concentrated.  The reaction 
mixture was dissolved in TEA (0.10 mL, 0.66 mmol) in CH2Cl2 (2 mL).  DMAP (11 
mg, 0.09 mmol) was added followed by Ac2O (0.06 mL, 0.66 mmol) at rt and the 
solution was allowed to react for 40 hr. The reaction mixture was concentrated 
and the residue with dissolved in EtOAc (5 mL) and extracted with EtOAc (2 x 10 
mL) and H2O (10 mL).  The combined organic phases were dried over MgSO4 
and concentrated.  The residue was purified by flash chromatography on silica 
gel (15→30% acetone in hexanes) to afford amide ester intermediate as a 
colorless oil (47 mg, 41% yield).  1H NMR (500 MHz, CDCl3) δ  4.1 (m, 2H), 2.20 
(m, 2H), 2.00 (s, 3H), 1.47 (m, 12H); 13C NMR (126 MHz, CDCl3) δ 174.5, 173.1, 
171.1, 82.7, 61.1, 52.2, 35.5, 27.8, 21.9, 20.9; IR (neat) cm-1 3348, 2979, 2358, 
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1745, 1669, 1364, 1227, 1121, 1037; HRMS (C12H21NO5, ESI): calculated 
282.1317 [M+Na]+1, found 282.1326. 
     5.14.2 Amide intermediate 
 
 
 
 
Figure 62. Amide Intermediate 
 
 
To a solution of the amide ester intermediate (28 mg, 0.108 mmol) in 
tBuOH (0.55 mL) was added Pb(OAc)4 (95.9 mg, 0.216 mmol) at 70 °C.  The 
solution was allowed to react overnight.  To the reaction mixture was added Et2O 
(4 mL) and NaHCO3 (0.11 g) and was allowed to stir for 10 min.  The reaction 
mixture was filtered through SiO2 and concentrated.  The residue was purified by 
flash chromatography on silica gel (20→40% acetone in hexanes) to afford the 
amide intermediate as a colorless oil (20 mg, 57% yield).  1H NMR (400 MHz, 
CDCl3) δ  4.05 (t, J = 6.6 Hz,  2H), 2.41 (m, 1H), 2.23 (m, 1H), 1.99 (s, 3H) 1.50 
(s, 3H), 1.46 (s, 9 H), 1.41 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 173.4, 171.0, 
154.2, 82.1, 79.4, 60.9, 58.1, 34.5, 28.4, 27.9, 24.2, 21.0; IR (neat) cm-1 3358, 
2980, 2359, 1726, 1369, 1242, 1045; HRMS (C16H29NO6, ESI): calculated 
354.1892 [M+Na]+1, found 354.1882.
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     5.14.3 Compound 27 
 
 
 
 
Figure 63. Compound 27 
 
 
To a solution of the amide intermediate (20 mg, 0.061 mmol) in MeOH 
(1.5 mL) was added K2CO3 (41 mg) at rt.  The solution was allowed to react for 
20 min.  The reaction mixture was diluted with CH2Cl2 (5 mL) and extracted with 
H2O (1 x 5 mL).  The organic layer was washed with brine (5 mL) and dried over 
MgSO4.  The solution was concentrated to yield compound 27 as a colorless oil 
(14 mg, 80% yield). 1H NMR (500 MHz, CDCl3) δ  3.7 (m, 2H), 2.2 (m, 1H), 2.15 
(m, 1H), 1.52 (s, 3H), 1.46 (s, 9 H), 1.41 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 
173.4, 154.7, 81.8, 79.4, 59.2, 58.5, 39.1, 28.4, 28.0, 23.8;  HRMS (C14H27NO5, 
ESI): calculated 312.1786 [M+Na]+1, found 312.1776; [α]D
23 = +10.0° (c = 0.9, 
CHCl3).
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5.15 Compound 28 
 
 
 
 
Figure 64. Compound 28 
 
 
To a solution of compound 22f (47 mg, 0.2 mmol) in THF (3.0 mL) was 
added a solution of LiAl(OtBu)3H (1.0 M in THF, 0.7 mL, 0.7 mmol) at -78 °C.  
The solution was allowed to warm to rt and react for 21 h.   The reaction was 
quenched with saturated potassium sodium tartrate, phases were separated, and 
aqueous phase was extracted with EtOAc (2 x 10 mL).  The combined organic 
phases were dried over MgSO4 and concentrated.  The residue was purified by 
flash chromatography on silica gel (20→60% EtOAc in hexanes) to afford 
compound 28 as a colorless oil (13 mg, 28% yield).  1H NMR (500 MHz, CDCl3) δ 
7.25 (m, 5H), 3.84 (d, J = 12.0 Hz, 1H), 3.69 (m, 2H), 3.54 (d, J = 12.0 Hz, 1H), 
3.17 (b, 2H), 2.95 (d, J = 13.7 Hz, 1H), 2.78 (d, J = 13.7 Hz, 1H), 2.10 (m, 1H), 
1.73 (m, 1H), 1.44 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 175.0, 136.5, 130.5, 
127.9, 126.8, 82.0, 65.4, 59.2, 51.7, 41.9, 38.9, 27.9; IR (neat) cm-1 3433, 2974, 
2932, 1773, 1725, 1453, 1369, 1145, 1104, 844; [α]D
23 = +4.1° (c= 1.3, CHCl3)
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5.16 Synthesis of Compound 43a 
 
 
     5.16.1 Acetyl intermediate 
 
 
 
 
Figure 65. Acetyl Intermediate 
 
 
To a solution of sodium hydride (60% in mineral oil, 0.13 g, 3.16 mmol) in 
THF (7.5 mL) was added di-tert-butyl malonate dropwise (0.68 g, 3.16 mmol) and 
the solution was stirred until gas evolution was complete.  To the reaction mixture 
was added benzyl 2-bromoethyl ether (0.5 mL, 3.16 mmol) and the solution was 
stirred under reflux until reaction completion was determined by TLC analysis.  
The reaction was quenched with saturated NH4Cl (6 mL) at 0 °C, phases were 
separated, and aqueous phase was extracted EtOAc (2 x 15 mL).  The combined 
organic phases were dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (5→20% EtOAc in hexanes) to 
afford the di-t-butyl 2-(2-(benzyloxy)ethyl)malonate intermediate as a colorless oil 
(0.75 g, 68% yield).  
To a solution of sodium hydride (60% mineral oil, 72 mg, 1.8 mmol) in THF 
(7 mL) was added the di-t-butyl 2-(2-(benzyloxy)ethyl)malonate intermediate (315 
mg, 0.9 mmol) and the solution was stirred until gas evolution was complete.  To 
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the reaction mixture was added 2-bromoethyl acetate (0.15 mL, 1.35 mmol) and 
the solution was stirred until reaction completion was determined by TLC 
analysis.  The reaction was quenched with saturated NH4Cl (6 mL) at 0 °C, 
phases were separated, and aqueous phase was extracted EtOAc (2 x 15 mL).  
The combined organic phases were dried over MgSO4 and concentrated.  The 
residue was purified by flash chromatography on silica gel (10→40% EtOAc in 
hexanes) to afford the acetyl intermediate as a colorless oil (358 mg, 91% yield). 
1H NMR (500 MHz, CDCl3) δ 7.29 (m, 5H), 4.43 (s, 2H), 4.06 (t, J = 7.2 Hz, 2H), 
3.43 (t, J = 6.9 Hz, 2H), 2.17 (m, 4H), 1.97 (s, 3H), 1.40 (s, 18H); 13C NMR (126 
MHz, CDCl3) δ 170.9, 170.1, 138.2, 128.4, 127.8, 127.6, 81.6, 73.1, 66.0, 60.9, 
55.5, 32.0, 30.9, 27.9, 21.0. 
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     5.16.2 Compound 42a 
 
 
 
 
Figure 66. Compound 42a 
 
 
To a solution of the acetyl intermediate (0.11g, 0.27 mmol) in MeOH (3 
mL) was added K2CO3 (0.15 g, 1.1 mmol) and the solution was stirred at rt until 
reaction completion was determined by TLC analysis.  The reaction mixture was 
diluted with CH2Cl2 and was extracted with CH2Cl2 (2 x 15 mL) and H2O (1 x 10 
mL).  The organic layer was dried over MgSO4 and concentrated to afford 
compound 42a as a colorless oil (94.7 mg, 90% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.30 (m, 5H), 4.45 (s, 2H), 3.64 (t, J = 6.3 Hz, 2H), 3.45 (t, J = 6.9 Hz, 
2H), 2.28 (bs, 1H), 2.22 (t, J = 6.6 Hz , 2H), 2.12 (t, J = 6.6 Hz, 2H), 1.40 (s, 18 
H); 13C NMR (126 MHz, CDCl3) δ 170.9, 138.1, 128.5, 127.9, 127.5, 81.6, 73.1, 
66.2, 59.0, 56.3, 35.3, 32.7, 27.9; HRMS (C22H34O6, ESI): calculated 417.2253 
[M+Na]+1, found 417.2245. 
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     5.16.3 Hydroxy Lactone intermediate 
 
 
 
 
Figure 67. Hydroxy Lactone Intermediate 
 
 
To a solution of acid 14 (0.05 mmol) in CH2Cl2 (3 mL) was added 
compound 42a (95 mg, 0.24 mmol) and the solution was stirred for 144 h at rt.  
The reaction was extracted with EtOAc (2 x 10 mL) and H2O (1 x 10 mL). The 
organic phase was dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (10→40% EtOAc in hexanes) to 
afford benzyl lactone intermediate (60 mg, 78% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.30 (m, 5H), 4.45 (q, J = 10.2 Hz, 2H), 4.29 (m, 2H), 3.59 (t, J = 6.2 
Hz, 2H), 2.65 (m, 1H), 2.37 (m, 2H), 2.13 (m, 1H), 1.43 (s, 9H); 13C NMR (126 
MHz, CDCl3) δ 175.4, 168.6, 138.1, 128.5, 127.8, 83.1, 73.1, 66.5, 53.6, 33.4, 
32.0, 27.9.
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To a solution of the benzyl lactone intermediate (44.3 mg, 0.14 mmol) in 
EtOAc (3 mL) was added Pd(OH)2 (20% on carbon, 9.7 mg, 0.07 mmol) and the 
solution was stirred under hydrogen pressure using a balloon filled with hydrogen 
gas at rt until reaction completion was determined by TLC analysis.  The reaction 
mixture was filtered through a plug of Celite® and concentrated to afford hydroxy 
lactone intermediate (28.7 mg, 90% yield). 1H NMR (500 MHz, CDCl3) δ 4.34 (m, 
2H), 3.79 (m, 2H), 2.63 (m, 1H), 2.38 (m, 1H), 2.31 (bs, 1H), 2.22 (m, 1H), 2.10 
(m, 1H), 1.46 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 176.2, 169.1, 83.6, 66.6, 
59.1, 53.9, 36.2, 32.7, 27.9. 
     5.16.4 Compound 43a 
 
 
 
 
Figure 68. Compound 43a 
 
 
To a solution of hydroxy lactone intermediate (28.7 mg, 0.12 mmol) in 
CH2Cl2 (2 mL) was added p-toluenesulfonic acid (11.5 mg, 0.6 mmol) and the 
solution was stirred at rt for 48 h.  The reaction was extracted with EtOAc (2 x 10 
mL) and H2O (1 x 10 mL). The organic phase was dried over MgSO4 and 
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concentrated to afford compound 43a as a white solid (18 mg, 92% yield). 1H 
NMR (500 MHz, CDCl3) δ 4.63 (m, 2H), 4.43 (m, 2H), 2.78 (m, 2H), 2.36 (m, 2H); 
13C NMR (126 MHz, CDCl3) δ 174.1, 66.8, 50.0, 32.6; HRMS (C7H8O4, ESI): 
calculated 157.0995 [M+H]+1, found 157.0498. 
5.17 Synthesis of Compound 43b 
 
     5.17.1 Benzyl intermediate 
 
 
 
 
Figure 69. Benzyl Intermediate 
 
 
To a solution of sodium hydride (60% in mineral oil, 65 mg, 1.62 mmol) in 
THF (7.0 mL) was added di-tert-butyl malonate dropwise (0.35 g, 1.62 mmol) and 
the solution was stirred until gas evolution was complete.  To the reaction mixture 
was added 2-bromoethyl acetate (0.18 mL, 1.62 mmol) and the solution was 
stirred until reaction completion was determined by TLC analysis.  The reaction 
was quenched with saturated NH4Cl (6 mL) at 0 °C, phases were separated, and 
aqueous phase was extracted EtOAc (2 x 15 mL).  The combined organic 
phases were dried over MgSO4 and concentrated.  The residue was purified by 
flash chromatography on silica gel (5→15% EtOAc in hexanes) to afford the di-t-
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butyl 2-(2-acetoxyethyl)malonate intermediate as a colorless oil (0.29 g, 60% 
yield).  
To a solution of sodium hydride (60% mineral oil, 78 mg, 1.94 mmol) in 
THF (7 mL) was added the di-t-butyl 2-(2-acetoxyethyl)malonate intermediate 
(291 mg, 0.84 mmol) and the solution was stirred until gas evolution was 
complete.  To the reaction mixture was added benzyl 3-bromopropyl ether (0.17 
mL, 0.97 mmol) and the solution was stirred until reaction completion was 
determined by TLC analysis.  The reaction was quenched with saturated NH4Cl 
(6 mL) at 0 °C, phases were separated, and aqueous phase was extracted 
EtOAc (2 x 15 mL).  The combined organic phases were dried over MgSO4 and 
concentrated.  The residue was purified by flash chromatography on silica gel 
(10→40% EtOAc in hexanes) to afford the benzyl intermediate as a colorless oil 
(212 mg, 49% yield). 1H NMR (500 MHz, CDCl3) δ 7.31 (m, 5H), 4.48 (s, 2H), 
4.06 (t, J = 7.2 Hz, 2H), 3.45 (t, J = 6.6 Hz, 2H), 2.16 (t, J = 7.2 Hz, 2H), 1.99 (s, 
3H), 1.88 (m, 2H), 1.49 (m, 2H), 1.44 (s, 18H); 13C NMR (126 MHz, CDCl3) δ 
171.0, 170.4, 138.6, 128.4, 127.7, 81.6, 72.9, 70.3, 60.8, 56.6, 30.6, 29.1, 27.9, 
24.5, 21.
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5.17.2 Compound 42b 
 
 
 
 
Figure 70. Compound 42b 
 
 
To a solution of the benzyl intermediate (146 mg, 0.32 mmol) in MeOH (3 
mL) was added K2CO3 (177 mg, 1.28 mmol) and the solution was stirred at rt 
until reaction completion was determined by TLC analysis.  The reaction mixture 
was diluted with CH2Cl2 and was extracted with CH2Cl2 (2 x 15 mL) and H2O (1 x 
10 mL).  The organic layer was dried over MgSO4 and concentrated to afford 
compound 42b as a colorless oil (117 mg, 88% yield). 1H NMR (500 MHz, CDCl3) 
δ 7.32 (m, 5H), 4.48 (s, 2H), 3.66 (m, 2H), 3.44 (t, J = 6.4 Hz, 2H), 2.09 (t, J = 6.5 
Hz, 2H), 2.01 (bs, 1H), 1.92 (m, 2H), 1.52 (m, 2H), 1.44 (s, 18H); 13C NMR (126 
MHz, CDCl3) δ 171.3, 138.6, 128.5, 127.7, 127.6, 81.6, 72.9, 70.3, 59.1, 57.1, 
35.3, 29.9, 28.0, 24.6; HRMS (C24H38O5, ESI): calculated 431.2404 [M+Na]
+1, 
found 431.2418. 
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     5.17.3 Lactone intermediate 
 
 
 
 
Figure 71. Lactone Intermediate 
 
 
To a solution of acid 14 (8.2 mg, 0.011 mmol) in CH2Cl2 (3 mL) was added 
compound 42b (90 mg, 0.22 mmol) and the solution was stirred for 144 h at rt.  
The reaction was extracted with EtOAc (2 x 10 mL) and H2O (1 x 10 mL). The 
organic phase was dried over MgSO4 and concentratedto afford lactone 
intermediate (73 mg, 99% yield). 1H NMR (500 MHz, CDCl3) δ 7.32 (m, 5H), 
4.48m (s, 2H), 4.30 (m, 2H), 3.49 (m, 2H), 2.66 (m, 1H), 2.22 (m, 1H), 2.11 (m, 
2H), 1.82 (m, 1H), 1.74 (m, 1H), 1.56 (m, 1H), 1.45 (s, 9H); 13C NMR (126 MHz, 
CDCl3) δ 175.3, 168.6, 138.4, 128.5, 127.8, 83.1, 73.0, 69.9, 66.2, 54.6, 31.9, 
30.8, 27.9, 25.2. 
To a solution of the lactone intermediate (73 mg, 0.22 mmol) in EtOAc (3 
mL) was added Pd(OH)2 (20% on carbon, 15.4 mg, 0.11 mmol) and the solution 
was stirred under hydrogen pressure using a balloon filled with hydrogen gas at 
rt until reaction completion was determined by TLC analysis.  The reaction 
mixture was filtered through a plug of Celite® and concentrated to afford lactone 
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intermediate (50.1 mg, 94% yield). 1H NMR (500 MHz, CDCl3) δ 4.31 (m, 2H), 
3.64 (m, 2H), 2.61 (m, 1H), 2.23 (m, 1H), 2.03 (m, 1H), 1.80 (m, 1H), 1.67 (m, 
1H), 1.51 (m, 1H), 1.45 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 175.5, 168.8, 83.3, 
66.3, 62.4, 54.5, 32.1, 30.2, 27.9. 
     5.17.4 Compound 43b 
 
 
 
 
Figure 72. Compound 43b 
 
 
To a solution of lactone intermediate (50.1 mg, 0.21 mmol) in CH2Cl2 (2 
mL) was added p-toluenesulfonic acid (39.1 mg, 0.21 mmol) and the solution was 
stirred at rt for 24 h.  The reaction was extracted with EtOAc (2 x 10 mL) and H2O 
(1 x 10 mL). The organic phase was dried over MgSO4 and concentrated to 
afford compound 43b as white solid (27.2 mg, 78% yield). 1H NMR (500 MHz, 
CDCl3) δ 4.56 (m, 2H), 4.39 (m, 1H), 4,37 (m, 1H), 2.86 (m, 1H), 2.41 (m, 1H), 
2.19 (m, 2H), 1.90 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 175.2, 168.6, 70.9, 
66.7, 50.3, 36.4, 30.3, 20.4; HRMS (C8H10O4, ESI): calculated 171.0651 [M+H]
+1, 
found 171.0654, [α]D
23 = - 2.5° (c =0.5, CHCl3)
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5.18 Synthesis of Compound 43c 
     5.18.1 Dialkylated intermediate 
 
 
 
 
Figure 73. Dialkylated Intermediate 
 
 
To a solution of sodium hydride (60% in mineral oil, 0.13 g, 3.16 mmol) in 
THF (7.5 mL) was added di-tert-butyl malonate dropwise (0.68 g, 3.16 mmol) and 
the solution was stirred until gas evolution was complete.  To the reaction mixture 
was added benzyl 2-bromoethyl ether (0.5 mL, 3.16 mmol) and the solution was 
stirred until reaction completion was determined by TLC analysis.  The reaction 
was quenched with saturated NH4Cl (6 mL) at 0 °C, phases were separated, and 
aqueous phase was extracted EtOAc (2 x 15 mL).  The combined organic 
phases were dried over MgSO4 and concentrated.  The residue was purified by 
flash chromatography on silica gel (5→20% EtOAc in hexanes) to afford the di-t-
butyl 2-(2-(benzyloxy)ethyl)malonate intermediate as colorless oil (0.75 g, 68% 
yield). 
To a solution of sodium hydride (60% mineral oil, 0.28 g, 0.8 mmol) in THF 
(7 mL) was added di-t-butyl 2-(2-(benzyloxy)ethyl)malonate intermediate and the 
solution was stirred until gas evolution was complete.  To the reaction mixture 
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was added N-tosyl aziridine (1M in THF, 0.16 g, 0.08 mmol) at 0 °C and the 
solution was allowed to slowly warm up to rt and was stirred until reaction 
completion was determined by TLC analysis.  The reaction was quenched with 
saturated NH4Cl (6 mL) at 0 °C, phases were separated, and aqueous phase 
was extracted EtOAc (2 x 15 mL).  The combined organic phases were dried 
over MgSO4 and concentrated.  The residue was purified by flash 
chromatography on silica gel (15→60% EtOAc in hexanes) to afford dialkylated 
intermediate (211 mg, 48% yield). 1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.2 
Hz, 2H), 7.28 (m, 7H), 4.80 (bs, 1H), 4.40 (s, 2H), 3.38 (t, J = 6.2, 2H), 2.89 (q, J 
= 6.9 Hz, 2H), 2.38 (s, 3H), 2.09 (t, J = 6.2 Hz, 2H), 2.01 (t, J = 7.3 Hz, 2H), 1.36 
(s, 18H); 13C NMR (126 MHz, CDCl3) δ 170.2, 143.3, 137.9, 136.8, 129.7, 128.5, 
127.9, 127.1, 81.9, 73.2, 66.1, 56.4, 39.3, 32.3, 27.8, 21.5. 
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     5.18.2 Compopund 42c 
 
 
 
 
Figure 74. Compound 42c 
 
 
To a solution of the dialkylated intermediate (58.1 mg, 0.11 mmol) in 
EtOAc (4 mL) was added Pd(OH)2 (20 % on carbon, 7.7 mg, 0.06 mmol) and the 
solution was stirred under hydrogen pressure using a balloon filled with hydrogen 
gas at rt until reaction completion was determined by TLC analysis.  The reaction 
mixture was filtered through a plug of Celite, the filtrate was concentrated under 
vacuum, to afford compound 42c as colorless oil (46.6 mg, 96% yield). 1H NMR 
(500 MHz, CDCl3) δ 7.70 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 8.0 Hz, 2H), 5.13 (bs, 
1H), 3.61 (t, J = 6.3 Hz, 2H), 2.90 (m, 2H), 2.40 (s, 3H), 2.03 (m, 4H), 1.39 (s, 
18H); 13C NMR (126 MHz, CDCl3) δ 170.6, 143.5, 136.8, 129.8, 127.2, 82.3, 
58.7, 56.4, 39.3, 35.3, 32.9, 27.9, 21.6; HRMS (C22H35NO7S, ESI): calculated 
480.2027 [M+Na]+1, found 480.2044.
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     5.18.3 Compound 43c 
 
 
 
 
Figure 75. Compound 43c 
 
 
To a solution of acid 14 (3.0 mg, 0.004 mmol) in CH2Cl2 (2 mL) was added 
compound 42c (36.5 mg, 0.08 mmol) and the solution was stirred for the 216 h at 
rt.  The reaction was extracted with EtOAc (2 x 10 mL) and H2O (1 x 10 mL). The 
organic phase was dried over MgSO4 and concentrated to afford lactone 
intermediate (28 mg, 92% yield). 
To a solution of lactone intermediate (26.4 mg, 0.07 mmol) in CH2Cl2 (1 
mL) was added excess trifluoroacetic acid (1 mL) and the solution was stirred 
until reaction completion was determined by TLC analysis.  The reaction was 
extracted with EtOAc (2 x 10 mL) and H2O (1 x 10 mL). The organic phase was 
dried over MgSO4 and concentrated to afford compound 43c as white solid (18.5 
mg, 87% yield).  1H NMR (500 MHz, CDCl3) δ 7.88 (d, J = 8 Hz,  2H), 7.34 (d, J = 
8 Hz , 2H), 4.48 (m, 1H), 4.32 (m, 1H), 4.07 (m, 2H), 2.73 (m, 1H), 2.52 (m, 1H), 
2.43 (s, 3H), 2.16 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 174.1, 170.1, 145.6, 
133.8, 129.7, 128.1, 66.9, 52.9, 43.0, 32.1, 28.5, 21.6; HRMS (C14H15NO5S, ESI): 
calculated 310.0744 [M+Na]+1, found 310.0745, [α]D
23 = - 6.4° (c =0.5, CHCl3).
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5.19 Synthesis of Compound 55a 
     5.19.1 Compound 54a 
 
 
 
 
Figure 76. Compound 54a 
 
 
To a solution of sodium hydride (60% in mineral oil, 0.14 g, 3.48 mmol) in 
THF (10 mL) was added di-t-butyl 2-methylmalonate intermediate (0.4 g, 1.74 
mmol) dropwise and the solution was stirred for 10 minutes at rt.  To the reaction 
mixture, N-tosylaziridine (1M in THF, 0.5 g, 2.61 mmol) was added dropwise at 
0°C.  The solution was allowed to warm to rt and react for 24 h.  The reaction 
was quenched with saturated NH4Cl (10 mL) at 0 °C, phases were separated, 
and aqueous phase was extracted with EtOAc (2 x 10 mL).  The combined 
organic phases were dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (15→60% EtOAc in hexanes) to 
afford the compound 54a as white solid (0.59 g, 80% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.70 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 4.8 (bs, 1H), 2.95 (q, J 
= 8.1 Hz, 2H), 2.40 (s, 3H), 1.91 (t, J = 7.3 Hz, 2H), 1.39 (s, 18H), 1.24 (s, 3H); 
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13C NMR (126 MHz, CDCl3) δ 171.3, 143.5, 136.8, 129.8, 127.2, 81.8, 53.6, 39.1, 
35.1, 27.9, 21.6, 20.1. HRMS (C21H33NO6S, ESI): calculated 450.1918 [M+Na]
+1, 
found 450.1927. 
     5.19.2 Compound 55a 
 
 
 
 
Figure 77. Compound 55a 
 
 
To a solution of acid (R)-14 (4.4 mg, 0.006 mmol) in CH2Cl2 (2 mL) was 
added compound 54a (50 mg, 0.12 mmol) and the solution was stirred for 96 h at 
rt.  The reaction was extracted with EtOAc (2 x 5 mL) and H2O (1 x 5 mL). The 
organic phase was dried over MgSO4 and concentrated to afford compound 55a 
as white crystalline solid (40.8 mg, 99% yield). 1H NMR (400 MHz, CDCl3) δ 7.94  
(d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 3.93 (m, 1H), 3.79 (m, 1H), 2.42 (m, 
4H), 1.96 (m, 1H), 1.32 (s, 3H), 1.21 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 
172.1, 169.5, 145.3, 134.8, 129.7, 128.3, 82.6, 53.5, 44.8, 31.3, 27.6, 21.7, 19.9; 
HRMS (C17H23NO5S, ESI): calculated 376.1195 [M+Na]
+1, found 376.1184. 
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5.20 Synthesis of Compound 55b 
     5.20.1 Compound 54b 
 
 
 
 
Figure 78. Compound 54b 
 
 
To a solution of sodium hydride (60% in mineral oil, 33 mg, 0.82 mmol) in 
THF (5 mL) was added di-t-butyl 2-ethylmalonate intermediate (100 mg, 0.41 
mmol) dropwise and the solution was stirred for 10 minutes at rt.  To the reaction 
mixture, N-tosylaziridine (1M in THF, 81 mg, 0.41 mmol) was added dropwise at 
0°C.  The solution was allowed to warm to rt and react for 24 h.  The reaction 
was quenched with saturated NH4Cl (10 mL) at 0 °C, phases were separated, 
and aqueous phase was extracted with EtOAc (2 x 10 mL).  The combined 
organic phases were dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (15→60% EtOAc in hexanes) to 
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afford the compound 54b as white solid (135 mg, 75% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.71 (d, J = 8.6 Hz, 2H), 7.27 (d, J = 8.0 Hz, 2H), 4.88 (t, J = 4.8 Hz, 
1H), 2.88 (q, J = 8.5 Hz, 2H), 2.39 (s, 3H), 1.92 (t, J = 6.1 Hz, 2H), 1.75 (q, J = 
9.1 Hz, 2H), 1.38 (s, 18H), 0.73 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 
170.6, 143.4, 136.8, 129.8, 127.2, 81.2, 57.6, 39.3, 31.7, 27.9, 25.9, 21.5, 8.3; 
HRMS (C22H35NO6S, ESI): calculated 464.2082 [M+Na]
+1, found 464.2077. 
     5.20.2 Compound 55b 
 
 
 
 
Figure 79. Compound 55b 
 
 
To a solution of acid (R)-14 (3.0 mg, 0.004 mmol) in DCE (1 mL) was 
added compound 54b (35 mg, 0.08 mmol) and the solution was stirred for 144 h 
at rt.  The reaction was extracted with EtOAc (2 x 5 mL) and H2O (1 x 5 mL). The 
organic phase was dried over MgSO4, concentrated, and filtered through a silica 
plug to afford compound 55a as white crystalline solid (16.0 mg, 55% yield). 1H 
NMR (400 MHz, CDCl3) δ 7.73 (m, 2H), 7.28 (m, 2H), 2.98 (m, 2H), 2.92 (m, 1H), 
2.62, (m, 1H), 2.43 (m, 3H), 1.76 (m, 1H), 1.65 (m, 1H), 1.38 (m, 1H), 1.38 (s, 
9H), 1.05 (m, 3H) ; 13C NMR (126 MHz, CDCl3) δ 175.3, 174.3, 143.6, 132.1, 
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129.8, 127.1, 80.8, 56.7, 45.3, 41.7, 31.7, 28.1, 21.6, 11.5. HRMS (C18H25NO5S, 
ESI): calculated 390.1351 [M+Na]+1, found 390.1343.  
5.21 Synthesis of Compound 55c 
     5.21.1 Compound 54c 
 
 
 
 
Figure 80. Compound 54c 
 
 
To a solution of sodium hydride (60% in mineral oil, 35 mg, 0.88 mmol) in 
THF (5 mL) was added allyl malonate intermediate (113.4 mg, 0.44 mmol) 
dropwise and the solution was stirred for 10 minutes at rt.  To the reaction 
mixture, N-tosylaziridine (1M in THF, 130 mg, 0.66 mmol) was added dropwise at 
0°C.  The solution was allowed to warm to rt and react for 24 h.  The reaction 
was quenched with saturated NH4Cl (10 mL) at 0 °C, phases were separated, 
and aqueous phase was extracted with EtOAc (2 x 10 mL).  The combined 
organic phases were dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (15→60% EtOAc in hexanes) to 
afford the compound 54c as white solid (86 mg, 43% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.71 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 7.8 Hz, 2H), 5.50 (m, 1H), 5.03 (m, 
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2H), 4.74 (t, J = 4.7 Hz, 1H), 2.92 (q, J = 8.6 Hz, 2H), 2.47 (t, J = 7.3 Hz, 2H), 
2.39 (s, 3H), 1.91 (t, J = 6.2 Hz, 2H), 1.38 (s, 18H); 13C NMR (126 MHz, CDCl3) δ 
170.1, 143.5, 136.8, 132.1, 129.8, 127.2, 119.3, 82.1, 56.9, 39.1, 37.7, 32.3, 
27.9, 21.6; HRMS (C23H35NO6S, ESI): calculated 476.2082 [M+Na]
+1, found 
476.2073. 
     5.21.2 Compound 55c 
 
 
 
 
Figure 81. Compound 55c 
 
 
To a solution of acid (R)-14 (3.0 mg, 0.004 mmol) in CH2Cl2 (1 mL) was 
added compound 54c (35 mg, 0.08 mmol) and the solution was stirred for 192 h 
at rt.  The reaction was extracted with EtOAc (2 x 5 mL) and H2O (1 x 5 mL). The 
organic phase was dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (15→60% EtOAc in hexanes) to 
afford compound 55c as white crystalline solid (21.0 mg, 74% yield). 1H NMR 
(400 MHz, CDCl3) δ 7.91 (d, J = 8.2 Hz, 2H), 7.31 (d, J = 8.2 Hz, 2H), 5.54 (m, 
1H), 5.04 (m, 2H), 3.87 (m, 1H), 3.79 (m, 1H), 2.55 (m, 1H), 2.41 (m, 4H), 2.31 
(m, 1H), 2.03 (m, 1H) 1.22 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 170.8, 168.4, 
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145.3, 134.7, 132.0, 129.7, 128.3, 120.0, 82.7, 57.2, 44.9, 37.9, 32.0, 27.6, 21.7; 
HRMS (C19H25NO5S, ESI): calculated 402.1351 [M+Na]
+1, found 402.1347.  
5.22 Synthesis of Compound 55d 
     5.22.1 Compound 54d 
 
 
 
 
Figure 82. Compound 54d 
 
 
  To a solution of sodium hydride (60% in mineral oil, 37 mg, 0.92 mmol) in 
THF (7 mL) was added di-t-butyl malonate dropwise (200 mg, 0.92 mmol) and 
the solution was stirred until gas evolution was complete.  To the reaction mixture 
was added 1-bromo-2-methylpropane (0.11 mL, 0.92 mmol) and the solution was 
stirred under reflux until reaction completion was determined by TLC analysis.  
The reaction was quenched with saturated NH4Cl (6 mL) at 0 °C, phases were 
separated, and aqueous phase was extracted EtOAc (2 x 15 mL).  The combined 
organic phases were dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (5→20% EtOAc in hexanes) to 
afford the di-t-butyl 2-isopentylmalonate intermediate as a colorless oil (205 mg, 
86% yield.
98 
 
To a solution of sodium hydride (60% in mineral oil, 47.5 mg, 1.19 mmol) 
in THF (6 mL) was added di-t-butyl 2-isopentylmalonate intermediate (205 mg, 
0.79 mmol) dropwise and the solution was stirred for 10 minutes at rt.  To the 
reaction mixture, N-tosylaziridine (1M in THF, 155.8 mg, 0.79 mmol) was added 
dropwise at 0°C.  The solution was allowed to warm to rt and react for 24 h.  The 
reaction was quenched with saturated NH4Cl (10 mL) at 0 °C, phases were 
separated, and aqueous phase was extracted with EtOAc (2 x 10 mL).  The 
combined organic phases were dried over MgSO4 and concentrated.  The 
residue was purified by flash chromatography on silica gel (15→60% EtOAc in 
hexanes) to afford the compound 54d as white solid (181.9 mg, 48% yield). 1H 
NMR (500 MHz, CDCl3) δ 7.70 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 4.77 
(t, J = 4.7 Hz, 1H), 2.88 (q, J = 8.6 Hz, 2H), 2.39 (s, 3H), 1.91 (t, J = 6.2 Hz, 2H), 
1.70 (m, 3H), 1.45 (m, 2H), 1.23 (s, 18H), 0.80 (d, J = 2.5 Hz, 6H); 13C NMR (126 
MHz, CDCl3) δ 170.7, 143.4, 136.8, 129.7, 127.2, 81.7, 57.2, 39.3, 32.7, 32.0, 
30.6, 28.3, 27.9, 22.5, 21.5; HRMS (C25H41NO6S, ESI): calculated 506.2552 
[M+Na]+1, found 506.2545.
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     5.22.2 Compound 55d 
 
 
 
 
Figure 83. Compound 55d 
 
 
To a solution of acid (R)-14 (3.5 mg, 0.004 mmol) in toluene (2 mL) was 
added compound 54d (45 mg, 0.09 mmol) and the solution was stirred for 204 h 
at 80 °C.  The reaction was extracted with EtOAc (2 x 5 mL) and H2O (1 x 5 mL). 
The organic phase was dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (15→60% EtOAc in hexanes) to 
afford compound 55d as white crystalline solid (15.7 mg, 41% yield). 1H NMR 
(400 MHz, CDCl3) δ 7.7 (d, J = 8.2 Hz, d), 7.25 (d, J = 8.2 Hz, 2H), 2.88 (m, 2H), 
2.40 (s, 3H), 2.11 (t, J = 7.1 Hz, 2H), 1.86 (m, 1H), 1.77 (m, 1H), 1.47 (s, 9H), 
0.84 (d, J = 6.9 Hz, 6H);  13C NMR (126 MHz, CDCl3) δ 174.6, 173.9, 143.7, 
136.5, 129.8, 127.2, 84.4, 55.6, 39.6, 35.1, 33.4, 28.1, 27.8, 22.5, 22.3, 21.6; 
HRMS (C21H31NO5S, ESI): calculated 432.1820 [M+Na]
+1, found 432.1819. 
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5.23 Synthesis of Compound 55e 
     5.23.1 Di-t-butyl 2-(but-2-yn-1-yl)malonate intermediate 
 
 
 
 
Figure 84. Di-t-butyl 2-(but-2-yn-1-yl)malonate Intermediate 
 
 
To a solution of sodium hydride (60% in mineral oil, 29 mg, 0.69 mmol) in 
THF (5 mL) was added di-t-butyl malonate dropwise (150 mg, 0.69 mmol) and 
the solution was stirred until gas evolution was complete.  To the reaction mixture 
was added 1-bromo-2-butyne (0.06 mL, 0.69 mmol) dropwise at 0 °C.  The 
reaction was allowed to warm to rt and react until reaction completion was 
determined by TLC analysis.  The reaction was quenched with saturated NH4Cl 
(6 mL) at 0 °C, phases were separated, and aqueous phase was extracted 
EtOAc (2 x 15 mL).  The combined organic phases were dried over MgSO4 and 
concentrated.  The residue was purified by flash chromatography on silica gel 
(5→10% EtOAc in hexanes) to afford the di-t-butyl 2-(but-2-yn-1-yl)malonate 
intermediate as a colorless oil (180 mg, 97% yield). 1H NMR (500 MHz, CDCl3) δ 
3.29 (t, J = 7.7 Hz, 1H), 2.60 (m, 2H), 1.73 (t, J = 2.6 Hz, 2H), 1.45 (s, 18H); 13C 
NMR (126 MHz, CDCl3) δ 167.0, 81.7, 77.5, 75.2, 53.5, 27.9, 18.7, 3.5.
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     5.23.2 Compound 54e 
 
 
 
 
Figure 85. Compound 54e 
 
 
To a solution of sodium hydride (60% in mineral oil, 23 mg, 0.56 mmol) in 
THF (4 mL) was added di-t-butyl 2-(but-2-yn-1-yl)malonate intermediate (74.1 
mg, 0.28 mmol) dropwise and the solution was stirred for 10 minutes at rt.  To the 
reaction mixture, N-tosylaziridine (1M in THF, 140 mg, 0.7 mmol) was added 
dropwise at 0°C.  The solution was allowed to warm to rt and react for 24 h.  The 
reaction was quenched with saturated NH4Cl (10 mL) at 0 °C, phases were 
separated, and aqueous phase was extracted with EtOAc (2 x 10 mL).  The 
combined organic phases were dried over MgSO4 and concentrated.  The 
residue was purified by flash chromatography on silica gel (15→60% EtOAc in 
hexanes) to afford the compound 54e as white solid (63.5 mg, 49% yield). 1H 
NMR (500 MHz, CDCl3) δ 7.78 (d, J = 8.6 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 5.18 
(bs, 1H), 3.04 (m, 2H), 2.54 (s, 2H), 2.41 (s, 3H), 2.03 (m, 2H), 1.71 (s, 3H), 1.43 
(s, 18H); 13C NMR (126 MHz, CDCl3) δ 169.1, 143.6, 135.8, 129.9, 127.2, 82.2, 
79.2, 73.3 
102 
 
56.3, 45.2, 42.3, 30.91, 27.8, 21.7, 3.5; HRMS (C24H35NO6S, ESI): calculated 
488.2082 [M+Na]+1, found 488.2077  
     5.23.3 Compound 55e 
 
 
 
 
Figure 86. Compound 55e 
 
 
To a solution of acid (R)-14 (2.0 mg, 0.002 mmol) in toluene (1 mL) was 
added compound 54e (25 mg, 0.05 mmol) and the solution was stirred for 192 h 
at 80 °C.  The reaction was extracted with EtOAc (2 x 5 mL) and H2O (1 x 5 mL). 
The organic phase was dried over MgSO4 and concentrated to afford compound 
55e as white crystalline solid (17.9 mg, 85% yield). 1H NMR (500 MHz, CDCl3) δ 
7.87 (m 2H), 7.32 (m, 2H), 3.87 (m, 2H), 2.47 (m, 1H), 2.41 (m, 3H), 2.09 (m, 
1H), 1.90 (m, 1H), 1.71 (m, 1H), 1.39 (s, 3H), 1.20 (s, 9H); 13C NMR (126 MHz, 
CDCl3) δ 173.9, 171.5, 143.8, 136.3, 129.9, 127.2, 80.1, 60.6, 55.6, 48.3, 45.5, 
42.1, 27.7, 21.6, 14.2, 3.6; HRMS (C20H25NO5S, ESI): calculated 414.1351 
[M+Na]+1, found 414.1343. 
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5.24 Synthesis of Compound 57d 
     5.24.1 Compound 56d 
 
 
 
 
Figure 87. Compound 56d 
 
 
To a solution of sodium hydride (60% in mineral oil, 45 mg, 1.12 mmol) in 
THF (5 mL) was added di-t-butyl 2-methylmalonate intermediate (127.9 mg, 0.56 
mmol) dropwise and the solution was stirred for 10 minutes at rt.  To the reaction 
mixture, N-nosylaziridine (1M in THF, 147 mg, 0.56 mmol) was added dropwise 
at 0°C.  The solution was allowed to warm to rt and react for 23 h.  The reaction 
was quenched with saturated NH4Cl (10 mL) at 0 °C, phases were separated, 
and aqueous phase was extracted with EtOAc (2 x 10 mL).  The combined 
organic phases were dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (15→60% EtOAc in hexanes) to 
afford the compound 56d as pale yellow oil (154 mg, 60% yield). 1H NMR (500 
MHz, CDCl3) δ 8.32 (d, J = 3.7 Hz, 2H), 8.04 (d, J = 3.7 Hz, 2H), 5.42 (bs, 1H), 
3.04 (q, J = 8.1 Hz, 2H), 1.93 (t, J = 5.7 Hz, 2H), 1.40 (s, 18H), 1.25 (s, 3H); 13C 
NMR (126 MHz, CDCl3) δ 174.3, 150.1, 145.9, 128.42, 124.5, 82.1, 53.7, 39.6, 
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35.2, 27.9, 20.3. HRMS (C20H30N2O8S, ESI): calculated 481.1620 [M+Na]
+1, 
found 481.1622 
     5.24.2 Compound 57d 
 
 
 
 
Figure 88. Compound 57d 
 
 
To a solution of acid (R)-14 (9.4 mg, 0.05 mmol) in CH2Cl2 (2 mL) was 
added compound 56d (45.4 mg, 0.1 mmol) and the solution was stirred for 96 h 
at rt.  The reaction was extracted with EtOAc (2 x 5 mL) and H2O (1 x 5 mL). The 
organic phase was dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (15→60% EtOAc in hexanes) to 
afford compound 57d as white crystalline solid (32.4 mg, 85% yield). 1H NMR 
(400 MHz, CDCl3) δ 8.33 (d, J = 3.6 Hz, 2H), 8.04 (d, J = 3.6 Hz, 2H), 3.09 (m, 
2H), 2.12 (m,1H), 2.06 (m, 1H), 1.45 (s, 9H), 1.41 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 176.3, 171.6, 150.1, 145.6, 128.5, 124.5, 83.5, 52.7, 39.6, 35.5, 28.8, 
20.9. HRMS (C16H20N2O7S, ESI): calculated 407.0888 [M+Na]
+1, found 407.0880.
105 
 
5.25 Synthesis of Compound 59 
     5.25.1 Compound 58 
 
 
 
 
Figure 89. Compound 58 
 
 
To a solution of sodium hydride (60% in mineral oil, 20mg, 0.46 mmol) in 
THF (4 mL) was added di-t-butyl 2-methylmalonate intermediate (100 mg, 0.46 
mmol) dropwise and the solution was stirred for 10 minutes at rt.  To the reaction 
mixture, N-tosylaziridine (1M in THF, 85 mg, 0.46 mmol) was added dropwise at 
0°C.  The solution was allowed to warm to rt and react for 23 h.  The reaction 
was quenched with saturated NH4Cl (10 mL) at 0 °C, phases were separated, 
and aqueous phase was extracted with EtOAc (2 x 10 mL).  The combined 
organic phases were dried over MgSO4 and concentrated.  The residue was 
purified by flash chromatography on silica gel (15→60% EtOAc in hexanes) to 
afford the compound 58 as white solid (130 mg, 68% yield). 1H NMR (500 MHz, 
CDCl3) δ7.71 (d, J = 8.6 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 4.71 (t, J = 6.3 Hz, 
1H), 3.21 (t, J = 7.1 Hz, 1H), 2.99 (q, J = 10.0 Hz, 2H), 2.41 (s, 3H), 1.97 (q, J = 
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10.3 Hz, 2H), 1.42 (s, 18H); 13C NMR (126 MHz, CDCl3) δ 168.5, 143.5, 136.8, 
129.8, 127.2, 82.1, 51.4, 41.2, 28.4, 27.9, 21.6.  
     5.25.2 Compound 59 
 
 
 
 
Figure 90. Compound 59 
 
 
To a solution of acid (R)-14 (5.2 mg, 0.007 mmol) in CH2Cl2 (2 mL) was 
added compound 54a (56.4 mg, 0.14 mmol) and the solution was stirred for 48 h 
at rt.  The reaction was extracted with EtOAc (2 x 5 mL) and H2O (1 x 5 mL). The 
organic phase was dried over MgSO4 and concentrated to afford compound 59 
as white crystalline solid (39.9 mg, 86% yield). 1H NMR (500 MHz, CDCl3) δ 7.90 
(m, 2H), 7.32 (m, 2H), 3.88 (m, 2H), 2.43 (m, 5H), 2.06 (m, 1H); 13C NMR (126 
MHz, CDCl3) δ 170.7, 169.1, 145.9, 134.3, 129.9, 128.3, 48.7, 32.2, 27.8, 21.8.  
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5.26 Synthesis of Compound 60 
 
 
 
 
Figure 91. Compound 60 
 
 
To a solution of compound 54a (61.7 mg, 0.14 mmol) in CH2Cl2 (2 mL) 
was added trifluoroacetic acid (1 mL) and the solution was stirred for 24 h at rt.  
The reaction was extracted with EtOAc (2 x 5 mL) and H2O (1 x 5 mL). The 
organic phase was dried over MgSO4 and concentrated to afford compound 60 
as white crystalline solid (38.6 mg, 90% yield). 1H NMR (500 MHz, CDCl3) δ 7.87 
(d, J = 8.0 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H), 3.87 (m, 2H), 2.52 (m, 1H), 2.42 (s, 
3H),  2.05 (m, 1H), 1.36 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 176.3, 171.9, 
145.9, 135.1, 129.8, 126.9, 62.2, 44.7, 30.7, 21.8, 19.4 HRMS (C13H15NO5S, 
ESI): calculated 320.0569 [M+Na]+1, found 320.0531.
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APPENDIX A 
 
NMR SPECTRA 
 
 
The 1H and 13C nuclear magnetic resonance (NMR) spectra were plotted 
on JEOL 400 and 500 MHz spectrometer using CDCl3 as a solvent at rt. The 
NMR chemical shifts (δ) are reported in ppm.  
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APPENDIX B 
 
CHROMATOGRAMS 
 
 
GC chromatograms were obtained using an Agilent 7890A.  The chiral 
column used was a Supelco Betadex 110 Fused Silica Capillary Column (30m x 
0.25mm x 0.25 μm).  HPLC chromatograms were obtained using an Agilent 1260 
Infinity. The chiral column used was a CHIRALCEL OJ-H (4.6 mm x 250 mm x 5 
μm). Analysis details can be found with each chromatogram. 
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Table 1. Substrate 22a 
 
 
 
 
 
GC Conditions: Column:  190916-13213, 30 m x 0.25 mm x 0.25 μm; Eluent 
Rate: 3 mL/ min; Temperature Ramp: 90 °C for 60 min, ramp 5 °C/min→170 °C, 
170 °C for 60 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Racemic 
Enantiomeric 
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Table 1. Substrate 22b 
 
 
 
  
 
GC Conditions: Column:  190916-13213, 30 m x 0.25 mm x 0.25 μm; Eluent 
Rate: 3 mL/ min; Temperature Ramp: 80 °C for 60 min, ramp 5 °C/min→170 °C, 
170 °C for 60 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Racemic  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enantiomeric 
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Table 1. Substrate 22c 
 
 
 
 
GC Conditions: Column:  190916-13213, 30 m x 0.25 mm x 0.25 μm; Eluent 
Rate: 3 mL/ min; Temperature Ramp: 90 °C for 60 min, ramp 5 °C/min→170 °C, 
170 °C for 60 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Racemic 
Enantiomeric 
  
178 
 
Table 1. Substrate 22d 
 
 
 
 
 
HPLC Conditions:  Column: HPLC OD-H 4.6 mm x 250 mm x 5 μm; Eluent 
Rate: 1mL/min; Eluent: 6% IPA/hexane; Monitoring wave: 254 nm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Racemic 
 
Enantiomeric 
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Table 1. Substrate 22e 
 
GC Conditions: Column:  190916-13213, 30 m x 0.25 mm x 0.25 μm; Eluent 
Rate: 3 mL/ min; Temperature Ramp: 50 °C for 30 min, ramp 2 °C/min→170 °C, 
170 °C for 10 min 
 
 
 
Racemic 
Enantiomeric 
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Table 1. Compound 22f 
 
 
 
 
 
 
 
 
GC Conditions: Column:  190916-13213, 30 m x 0.25 mm x 0.25 μm; Eluent 
Rate: 3 mL/ min; Temperature Ramp:  120 °C for 60 min, ramp 5 °C/min→170 
°C, 170 °C for 60 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Racemic 
 
Enantiomeric 
  
181 
 
Table 1. Compound 22g 
 
 
 
 
 
GC Conditions: Column:  190916-13213, 30 m x 0.25 mm x 0.25 μm; Eluent 
Rate: 3 mL/ min; Temperature Ramp:  120 °C for 60 min, ramp 5 °C/min→170 
°C, 170 °C for 60 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Racemic 
 
 
 
 
Enantiomeric 
  
182 
 
Figure 15. Compound 24 
 
 
 
 
 
 
GC Conditions: Column:  190916-13213, 30 m x 0.25 mm x 0.25 μm μm; Eluent 
Rate: 3 mL/ min; Temperature Ramp:  90 °C for 60 min, ramp 5 °C/min→170 
°C, 170 °C for 60 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Racemic 
 
Enantiomeric 
  
183 
 
Figure 15. Compound 25 
 
 
GC Conditions: Column:  190916-13213, 30 m x 0.25 mm x 0.25 μm; Eluent 
Rate: 3 mL/ min; Temperature Ramp:  120 °C for 60 min, ramp 5 °C/min→170 
°C, 170 °C for 60 min 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
Enantiomeric 
Racemic 
  
184 
 
Figure 15. Compound 26 
 
 
 
 
 
GC Conditions: Column:  190916-13213, 30 m x 0.25 mm x 0.25 μm; Eluent 
Rate: 3 mL/ min; Temperature Ramp:  120 °C for 60 min, ramp 5 °C/min→170 
°C, 170 °C for 60 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Racemic 
 
Enantiomeric 
  
185 
 
Figure 15. Compound 27 
 
 
 
 
 
GC Conditions: Column:  190916-13213, 30 m x 0.25 mm x 0.25 μm; Eluent 
Rate: 3 mL/ min; Temperature Ramp: 90 °C for 60 min, ramp 5 °C/min→170 °C, 
170 °C for 60 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Racemic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enantiomeric 
  
186 
 
Table 2. Compound 43a 
 
GC Conditions: Column:  190916-13213, 30 m x 0.25 mm x 0.25 μm; Eluent 
Rate: 3 mL/ min; Temperature Ramp:  120 °C for 60 min, ramp 5 °C/min→170 
°C, 170 °C for 60 min 
 
 
 
 
Racemic 
 
 
 
 
Enantiomeric 
  
187 
 
Table 2. Compound 43b 
 
 
HPLC Conditions:  Column: HPLC OD-H 4.6 mm x 250 mm x 5 μm; Eluent 
Rate: 1mL/min; Eluent: 5% IPA/hexane; Monitoring wave: 210 nm 
 
 
 
Racemic 
 
 
 
 
Enantiomeric 
 
 
 
 
 
 
  
188 
 
Table 2. Compound 43c 
 
 
GC Conditions: Column:  190916-13213, 30 m x 0.25 mm x 0.25 μm; Eluent 
Rate: 3 mL/ min; Temperature Ramp:  140 °C for 60 min, ramp 5 °C/min→170 
°C, 170 °C for 60 min 
 
 
 
Racemic 
 
 
 
Enantiomeric 
  
189 
 
Table 3. Compound 57d 
 
HPLC Conditions:  Column: HPLC OD-H 4.6 mm x 250 mm x 5 μm; Eluent 
Rate: 1mL/min; Eluent: 5% IPA/hexane; Monitoring wave: 254 nm 
 
 
 
Racemic 
 
 
 
Enantiomeric 
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Table 4. Compound 54a 
 
 
 
HPLC Conditions:  Column: HPLC OD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 3% IPA/hexane; Monitoring wave: 254 nm 
 
 
 
Racemic 
 
 
 
Enantiomeric 
 
 
 
 
 
 
 
  
191 
 
Table 4. Compound 54b 
 
 
 
HPLC Conditions:  Column: HPLC OD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 1% IPA/hexane; Monitoring wave: 210 nm 
 
 
 
 
Racemic 
 
 
 
Enantiomeric 
 
 
 
 
 
  
192 
 
Table 4. Compound 54c 
 
 
 
 
HPLC Conditions:  Column: HPLC OD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 9% IPA/hexane; Monitoring wave: 210 nm 
 
 
 
Racemic 
 
 
 
Enantiomeric 
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Table 4. Compound 54d 
 
 
 
 
HPLC Conditions:  Column: HPLC OD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 9% IPA/hexane; Monitoring wave: 210 nm 
 
 
 
Racemic 
 
 
 
Enantiomeric 
  
194 
 
Table 4. Compound 54e 
 
 
 
 
HPLC Conditions:  Column: HPLC OD-H 4.6 mm x 250 mm x 5 μm; Eluent Rate: 
1mL/min; Eluent: 9% IPA/hexane; Monitoring wave: 210 nm 
 
 
 
Racemic 
 
 
 
Enantiomeric 
 
